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Abstract 
Within individual cells, the opposing processes of proliferation and apoptosis are 
precisely regulated. When this regulatory balance is interrupted, cells may become 
abnormal or even transformed. Understanding how to reverse or avoid these 
detrimental transformative processes begins with an intimate knowledge of the 
processes governing the cell cycle and apoptosis.  Cell proliferation is governed by the 
cell cycle machinery. The cell cycle is driven by Cyclin-dependent kinase (Cdk) activity, 
which is dependent on the availability of specific Cyclin binding partners. The amount 
of available Cyclin is tightly controlled by a ubiquitin ligase protein complex called the 
anaphase promoting complex/cyclosome (APC/C.) This complex mediates the timely 
ubiquitylation and degradation of cell cycle regulators in order to control mitotic exit, 
the G1/S transition and to respond to signals emanating from spindle assembly 
checkpoint.  
Given the importance of the APC/C, cells develop many ways to regulate APC/C 
activity. Post-translational modifications of the APC/C have been shown to alter its 
functionality, and many pseudosubstrate-based inhibitors have been discovered. 
Moreover, inhibitors such as Emi1 and Emi2, have been showed to inhibit the APC/C 
through their own intrinsic ubiquitin E3 ligase activities.  Utilizing the Xenopus egg 
extract system, our laboratory has previously demonstrated that the RING domain-
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containing ubiquitin E3 ligase Xnf7 can inhibit Xenopus APC/C activity. In the thesis, we 
have identified TRIM39 as an Xnf7-related human regulator of the APC/C. Our study 
showed that TRIM39 restrains the ability of the APC/C to ubiquitylate Cyclin B in vitro 
and attenuates the degradation of Cyclin B and geminin when TRIM39 is incubated in 
cell lysates. Notably, it has been reported that TRIM39 activity is responsible for the 
accumulation of the Bax-interacting protein (and activator) MOAP-1 following 
etoposide-induced DNA damage. Our data indicated that MOAP-1 is a novel APC/C 
substrate, and that the ligase activity of TRIM39 appears to be essential for preventing its 
degradation. We further demonstrated that decreased levels of the APC/C activator 
Cdh1 induces MOAP-1 protein accumulation, thereby promoting DNA damage-induced 
apoptosis in 293T, PC3 and H1299 cells. This study illustrates a potential function for the 
APC/C in DNA damage induced apoptosis and also demonstrates that TRIM39 
regulates both the cell cycle and apoptosis via APC/C inhibition. 
To extend our observations regarding the role for TRIM39 in APC/C regulation, 
we investigated effects on the cell cycle via real-time imaging microscopy. We found 
cells arrest at G1/S in TRIM39 depleted RPE cells, a cell line which is commonly used for 
cell cycle analysis. This arrest phenotype is not observed in 293T, PC3 and H1299 cells 
which bear mutant p53 alleles. Further analysis showed that TRIM39 depleted RPE cells 
upregulate many genes that function downstream of p53 activity, such as the cdk 
inhibitor p21—thus, arresting cells at G1/S and reducing proliferation. The reduced 
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growth can be rescued by p53 knockdown. Mechanistically, TRIM39 interacts with p53 
and promotes destruction of p53 by ubiquitylation. This ubiquitylation is independent 
of the activity of the most intensively studied p53-directed E3 ligase, MDM2; depletion 
of both MDM2 and TRIM39 has a synergistic effect on p53 accumulation. This elevated 
p53 leads to more apoptosis in cancer cells bearing wildtype p53. Consequently, TRIM39 
depletion might be employed as a combination treatment with MDM2 inhibitor, such as 
nutlin-3a, to stimulate tumor cell death. 
In the thesis, we have found TRIM39 inhibits both the APC/C and p53. Both are 
essential regulators of cell cycle and apoptosis. Moreover, we have determined that the 
inhibitory activity of TRIM39 requires its E3 ligase activity. Future experiments will be 
directed towards investigating how TRIM39 protein stability and ligase activity are 
regulated to understand more fully the physiological situations in which TRIM39 is able 
to exert its ability to modulate the cell cycle and apoptosis.   I will also discuss some 
preliminary data regarding changes in TRIM39 ligase activity induced by Chk1 and 
changes in TRIM39 protein abundance regulated by  polo-like kinase 1(Plk1). Chk1 and 
Plk1 are essential kinases for cell cycle checkpoint and progression. Connecting Chk1 
and Plk1 to TRIM39 may provide a more thorough understanding of TRIM39’s ability to 
control the APC/C inhibition and p53 ubiquitylation in response to cell cycle or cell 
damage cues. Since the APC/C and p53 both can regulate cell cycle and apoptosis, 
further investigations into the involvement of TRIM39 in the life-or-death decision will 
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be of great interest.     
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1. Introduction   
1.1 Cell cycle progression  
Cell division is achieved by a series of ordered events, including DNA 
replication, spindle formation, chromosome segregation, cytokinesis and entry into the 
next division cycle. The cell cycle can be divided into four stages: G1 (Gap1), S 
(synthesis), G2 (Gap2) and M (mitosis) stage (Fig. 1.1). Through G1 to S phase, cells 
grow and produce their complement of proteins and nucleotides to prepare for accurate 
DNA replication in S phase. After DNA duplication, cells keep growing, and in the G2 
phase, sister chromatids are connected in a cohesion-dependent protein complex. 
Duplicated chromosomes and organelles are then separated into two daughter cells 
during mitosis. Mitosis can be further subdivided into five sequential phases, known as 
prophase, prometaphase, metaphase, anaphase, and telophase.  Prophase is a stage 
when the chromosomes become condensed and is followed by prometaphase when the 
nuclear membrane breaks down and mitotic spindle fibers attach at the kinetochore. 
Metaphase is reached when the spindle structure has properly formed and all of the 
chromosomes are aligned in preparation for sister chromatid segregation.  This process 
is tightly regulated by the spindle assembly checkpoint (SAC) to ensure chromosomes 
attach to spindles properly.  During anaphase, the SAC is inactivated to trigger 
proteolytic cleavage of cohesin, causing sister-chromatids to separate to the two 
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opposing poles of the cell, pulled by the spindle microtubules. The chromosomes are 
then decondensed and the nuclear membrane reforms in telophase. After M phase, 
cytokinesis begins.  In this process, the cytoplasm and other cellular contents divide into 
the two daughter cells, completing cell division, and leading to G1 phase entry (Morgan, 
2007; Viallard et al., 2001).  
When there is a lack of sufficient growth factors and nutrients, or when cells are 
fully differentiated, such as neurons, cells can also exit G1 into a quiescent G0 phase 
through a cell cycle checkpoint called the restriction point. Cells in G0 phase can reenter 
G1 and continue to divide through cell cycle progression when growth factors stimulate 
cells. In contrast, another cellular state, called senescence, occurs when cells stop 
division and cannot re-enter the cell cycle. Senescent cells are characterized by their flat 
and enlarged shape; increased expression of β-galactosidase and Cyclin-dependent 
kinase inhibitors; and a transcriptionally inactive heterochromatic structure (Kuilman et 
al., 2010; Sherwood et al., 1988). Senescence plays a role in tumor suppression since it 
can suppress cell proliferation. It is also related to aging, as acculmulation of senescent 
cells leads to impaired tissue homeostasis and eventually induce aging. (Collado et al., 
2005; Sharpless, 2004) 
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1.1.1 Cdk kinase activity   
Cyclin-dependent kinase (Cdk) activity controls progression of the cell cycle, and 
the activity of each kinase depends on the availability of its Cyclin partner. Cylins D1, 
D2 and D3 pair with the G1 Cdk4/6. These complexes phosphorylate retinoblastoma 
protein (Rb), leading to its dissociation from and activation of the transcription factor 
E2F.   E2F transcriptional  targets, including Cyclin E1 and E2, are required for the G1/S 
transition. Cylin E/Cdk2 promotes the G1/S transition and Cyclin A2 synthesis. Cyclin 
A2 then pairs with Cdk2 to enter S phase and trigger DNA and centrosome replication. 
When cells are ready, Cyclins B1 and B2 bind to Cdk1 and, together with 
CyclinA2/Cdk1, drive entry into mitosis. Activation of the CylinA,B/Cdk1 complexes 
initiates prophase and leads to nuclear membrane breakdown. When Cyclin B/Cdk1 
loses its activity, cells exit mitosis for G1 (Draetta and Beach, 1988; Morgan, 2007). 
Cdk activity can also be regulated by Cdk inhibitor proteins (CKIs) in G1 phase. 
These CKIs are potent inhibitors of Cyclin/cdk complexes and are activated when cells 
face an unfavorable environment or DNA damage. There are two families of CKIs, the 
Cip/Kip family (CDK interacting protein/Kinase inhibitory protein) and the INK4a/ARF 
family (Inhibitor of Kinase4a/ Alternative Reading Frame). The Cip/Kip family includes 
p21, p27 and p57. These proteins can arrest cells at G1 both by inhibiting Cyclin E, 
A/Cdk2 and by activating the G1 Cyclin D/Cdk complex via binding to the Cyclin/Cdk 
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complexes. The INK4a/ARF family, including p15, p16, p18 and p19, can inhibit Cdk4 
and Cdk6 activity by binding to Cdk4 or Cdk6 (Sanchez and Dynlacht, 2005) (Morgan, 
2007; Viallard et al., 2001) (Sherr and Roberts, 1999).    
1.1.2 Ubiquitin ligase in the cell cycle 
Timely regulation of cell cycle progression is mainly achieved by controlling the 
abundance of key regulatory proteins. Waves of protein expression levels are 
established with coordinated degradation by the ubiqutin-proteasome system (UPS) 
(Ciechanover, 1998). Ubiquitylation, a post-translational modification process in which 
ubiquitin peptides are conjugated to Lys residues of cell regulatory proteins, has a major 
influence on protein activity either via  proteasome-mediated degradation or non-
proteolytic regulation. Target substrates are processed sequentially by a series of 
ubiquitin enzymes: an ubiquitin E1 activating enzyme, an E2 conjugating enzyme and 
an E3 ligase (Fig. 1.2) (Budhidarmo et al., 2012; Wasch and Engelbert, 2005). The 
specificity of substrate determination is controlled largely by E3 ligases. There are nearly 
600 E3 ligases in humans and many E3 ligases harbor a Really Interesting New Gene 
(RING) domain or a Homologous to the E6-AP Carboxyl Terminus (HECT) domain. The 
RING domain is a conserved motif, often containing Cys-X2-Cys-X11-16-Cys-X-His-X2-
Cys-X2-Cys-X7-74-Cys-X2-Cys (C3HC4), where X can be any amino acid. There are 
several C3HC4 type RING-containing E3 ligase proteins, including Cbl, BRCA1, and 
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murine double minute 2 (MDM2). Another type of RING domain, in which Cys5 is 
substituted with His (H2 type), is found in Rbx1 and APC11 proteins. These two 
proteins are subunits of the Skp1-Cullin-F-box (SCF) and Anaphase promoting 
complex/cyclosome (APC/C) complexes, respectively (Lipkowitz and Weissman, 2011) 
(Ikeda and Inoue, 2012) (Benanti, 2012). 
SCF and APC/C are the most studied and characterized E3 ligases involved in 
controlling cell cycle progression. SCF is composed of: a structural subunit, cullin; a 
RING domain containing protein Rbx1; an adaptor protein S phase kinase-associated 
protein 1 (Skp1); and one of up-to 69 human F-box proteins, which serves to recognize 
specific substrates. Therefore, the activity of SCF toward its substrates is modulated by 
the availability of F-box proteins.  In most F-box proteins, including F-box/WD repeat-
containing protein 7 (FBW7) and β-transducin repeat containing protein (β-TrCP), the F-
box domain interacts with phosphorylated substrates. This interaction regulates SCF 
activity. Although SCF E3 ligases are active throughout the cell cycle, most SCF 
substrates are targeted in G1 and S phase. SCF (including SCFFbx4-αBCrystallin, SCFFbxw8, SCFβ-
Trcp, SCFFbxo31, and SCFSkp2) can ubiquitylate Cyclin D1, and SCFFbw7 is reported to 
ubiquitylate phosphorylated Cyclin E and Myc (Barbash and Diehl, 2008) (Nakayama et 
al., 2001). Moreover, SCFSkp2 targets Cyclin dependent kinase inhibitors p21, p27 and p57 
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(Lipkowitz and Weissman, 2011; Nakayama and Nakayama, 2006) (Benanti, 2012) 
(Cardozo and Pagano, 2004). 
The APC/C also contains a RING domain protein and is active during mitosis 
and G1 phase. Its co-activators, Cdc20 and Cdh1, associate with the APC/C at mitosis 
and G1, respectively, and mediate substrate recruitment. The APC/C is activated in 
mitosis to degrade Cyclin A in prophase, followed by Cyclin B and the separase 
inhibitor, securin, to transit the cycle from metaphase to anaphase. The APC/C is 
activated in G1 to prevent premature entry into S phase through the degradation of 
Cyclins and proteins regulating replication, such as geminin. Other cell cycle regulators 
ubiquitylated by the APC/C include polo-like kinase 1 (Plk1), p21 and Aurora B 
(Shirayama et al., 1999) (Geley et al., 2001) (Lindon and Pines, 2004) (Amador et al., 2007) 
(Nguyen et al., 2005). Interestingly, crosstalk between the APC/C and SCF occurs. SCF 
promotes the activation of the APC/C by degrading its inhibitor, Early mitotic inhibitor 1 
(Emi1), during interphase, while Skp2 is targeted by APC/C leading to SCF inactivation 
(Bashir et al., 2004) (Moshe et al., 2004) (Cardozo and Pagano, 2004). Thus, these two 
RING-containing ligases work closely together to regulate and promote cell cycle 
progression. 
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1.2 DNA damage response 
The human genome is under constant threat from both exogenous sources, such 
as ionizing radiation, ultraviolet radiation (UV), and alkylating chemicals, and 
endogenous sources, such as reactive oxygen species, nitrogen species, and DNA 
replication errors (Lindahl, 1993). Given the importance of maintaining the integrity of 
the genome, cells have developed robust mechanisms to overcome these damages. These 
mechanisms include sensing DNA damage, using cell cycle check points, and repairing 
DNA. In the case of severe damage, cells will activate a death pathway, such as 
apoptosis (Jackson and Bartek, 2009). 
1.2.1 DNA damage sensing signaling and cell cycle check point 
DNA damage sensors detect lesions of DNA damage and initiate the DNA 
damage response. The key sensors are the protein kinases ATM and ATR, which are 
recruited and activated by double strand breaks (DSBs) or single strand breaks (SSBs) 
(Jackson and Bartek, 2009). ATM is recruited by the MRN complex (Mre11- Rad50-
Nbs1), and will dissociate from inactive dimers and undergo autophosphorylation after 
DSBs and SSBs. Upon sensing SSBs, ATR is recruited by RPA and ATRIP, and PCNA-
related 911 (Rad9-Rad1-Hus1) is recruited to the complex with DNA (Harper and 
Elledge, 2007) (Lee and Paull, 2005). ATM and ATR propagate the signal by 
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phosphorylating many substrates including Chk1 and Chk2 kinases, which play a key 
role in inducing cell cycle arrest and DNA repair.  
Chk1/2 go on to phosphorylate Cdc25A, a phosphatase that targets Cdk. This 
phophorylation creates a docking site for SCFβ-Trcp and consequently Cdc25A 
ubiquitylation and degradation. Destruction of Cdc25A interferes with progression of S 
phase due to the accumulation of inhibitory phosphorylations on Cdk, thereby leading 
to the intra-S checkpoint. Phosphorylation of Cdc25C by Chk1/2 sequesters 14-3-3 and 
inhibits Cdc25C dephosphorylation of Cdk. Together, this inhibits entry into mitosis 
(G2/M checkpoint) (Harper and Elledge, 2007) (Guardavaccaro and Pagano, 2006). In 
addition, Chk1/2 can phosphorylate Rb to promote its inhibitory binding to E2F. Chk1/2 
can also phosphorylate p53 to prevent its degradation and to promote its transcriptional 
activity. The two phosphorylations on Rb and p53 result in G1/S arrest. Taken together, 
Chk1/2 ensure that cells arrest at G1/S, intra S, or G2 during the DNA damage response. 
This arrest is necessary to provide cells with time to repair their damaged DNA (Inoue 
et al., 2007) (Nowsheen and Yang, 2012).  
1.2.2 Check point recovery and adaptation     
During G2/M arrest, polo-like kinase 1 (Plk1) is inhibited by ATM/ATR 
signaling, preventing Plk1 from phosphorylating and inhibiting wee1, a kinase that in 
turn mediates an inhibitory phosphorylation of Cdk. Specifically, this Plk1 
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phosphorylation of wee1 facilitates wee1 ubiquitylation, so Plk1 inhibition causes wee1 
accumulation, robust Cdk inhibition, and G2/M arrest. Plk1 inhibition also prevents 
activation of the APC/C since APC/C activation requires phosphorylation of its subunits 
by Plk1 (Tsvetkov and Stern, 2005) (Guardavaccaro and Pagano, 2006) (Smits et al., 
2000).  
Plk1 is reported to be an activating kinase for Cdc25, although this function is 
dispensable in unstressed cells. However, this function is important for recovery from 
G2/M arrest. Phosphorylation of Cdc25B by Plk1 is required for mitotic entry after DNA 
damage (van Vugt et al., 2004).  Plk1 is also involved in the inactivation of Chk1 in that it 
phosphorylates Claspin, an activator of Chk1, targeting it for SCFβ-Trcp-mediated 
ubiquitylation and destruction (Gewurz and Harper, 2006). Plk1 was also shown to 
phosphorylate 53BP1 and Chk2 to inactivate G2 arrest and promote re-entry into the cell 
cycle (van Vugt et al., 2010). Furthermore, Plk1 can phosphorylate a p53 negative 
regulator, GTSE1, which can promote p53 shuttling out of the nucleus and degradation 
(Bahassi el, 2011) (Liu et al., 2010).  
It has been reported in yeast, Xenopus, and human cancer cell lines that cell 
division will occur even in the presence of unrepaired DNA after a prolonged G2 arrest. 
This process is called checkpoint adaptation. In yeast, checkpoint adaptation requires 
the activity of polo-like kinase, Cdc5, CKII, phosphatases Ptc2 and Ptc3, and inactivation 
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of Rad53 (Chk2 homolog) and Chk1. Recent data also showed that overexpression of 
Cdc5 will override DSB-induced signaling (Bahassi el, 2011).  In Xenopus, Plk1 
phophorylates Claspin, and this phosphorylation reduces the association between 
Claspin and chromatin, leading to Chk1 inactivation (Lupardus and Cimprich, 2004). In 
human cells, it has been suggested that Chk1 inhibition and Plk1 kinase activation are 
required for adaptation. It has been postulated that adaptation could move the cell into 
another cell cycle phase for cell death (mitotic catastrophe) or DNA repair (G1/S arrest) 
in different stages of arrest. However, apoptosis should be a safer and more efficient 
strategy than checkpoint adaptation for preventing the transmission of damage to future 
generations. Moreover, checkpoint adaptation is proposed to play a role in cancer 
development by allowing the propagation of oncogenic genomic aberrations (Syljuasen 
et al., 2006). Interestingly, high Plk1 expression has been reported in many types of 
cancer (Takai et al., 2005). This elevation may provide evidence correlating checkpoint 
adaptation and cancer development. Figure 1.3 summarizes the DNA damage response 
described above.           
1.3 APC/C 
1.3.1 The role of APC/C  
The APC/C is a large multisubunit E3 ubiquitin ligase that targets substrate 
degradation through the 26S proteasome. Temporal regulation of APC/C activity and 
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substrate specificity is critical for APC/C-mediated coordination of cell cycle 
progression. As described earlier, the APC/C degrades many essential regulators in 
mitosis and accurately controls chromosome segregation to prevent chromosome 
instability. Besides its role in mitotic exit, the APC/CCdh1 is involved in maintaining low 
Cdk1 activity in G1 by degrading Cyclin A, Cyclin B, Cdc25A and Skp2. APC/CCdh1 also 
regulates DNA replication by controlling the degradation of geminin and cdc6, which 
regulate replication and pre-replication complex formation (Manchado et al., 2010) (Fig. 
1.5).   
 Aside from its roles in cell cycle progression, the APC/C has been reported to 
control programmed cell death and neural growth.  The APC/CCdh1 is highly expressed 
in the brain. It inhibits axon growth by degrading the transcription co-repressor SnoN 
and Id2 (Konishi et al., 2004; Lasorella et al., 2006; Stegmuller et al., 2006). Moreover, 
Cdh1 depletion in neuroblastoma and post-mitotic neurons leads to Cyclin B 
accumulation and apoptosis. This apoptosis is suggested to result from cell cycle re-
entry when Cyclin B levels are elevated.  Such elevated Cyclin B is found in 
degenerating brains with Alzheimer’s disease or stroke (Almeida et al., 2005). Another 
study substantiates the role of Cdh1 in attenuation of neuronal apoptosis (Maestre et al., 
2008). Stimulating the N-methyl-D-aspartate receptors in such a way as to mimic 
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neurodegenerative diseases leads to Cdk5 mediated-phosphorylation and inhibition of 
Cdh1. This inhibition results in Cyclin B accumulation and apoptosis.  
The APC/C is also involved in metabolic regulation: it is reported to ubiquitylate 
glycolysis-promoting enzyme 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 
isoform 3 (PFKFB3) in T lymphocytes and cortical neuron cells (Colombo et al., 2010; 
Rodriguez-Rodriguez et al., 2012). The APC/C can also affect glutaminolysis by targeting 
glutaminase-1. Moreover, the APC/C can regulate nucleotide biosynthesis by targeting 
thymidine kinase 1 and ribonucleotide reductase 2 (Manchado et al., 2010).   
1.3.2 APC/C structure 
The APC/C is composed of at least fifteen subunits, and the recognition of 
substrates is mediated by one of its co-activators, Cdh1 or Cdc20, during the mitotic cell 
cycle, whereas Ama1 acts in yeast meiosis (Dong et al., 1997) (Schwab et al., 1997) 
(Cooper et al., 2000) (Fig. 1.4).  APC/C subunits are held together by APC1, the largest of 
the subunits. The cullin-domain of APC2 is associated with the RING-finger domain of 
APC11 to form the catalytic subcomplex, which catalyzes the direct transfer of a 
ubiquitin moiety from the E2 to its substrates (Pines, 2011). The majority of the other 
subunits, such as APC3/Cdc27, APC5, APC6 and APC7, contain a series of 
tetratricopeptide repeats (TPRs) that mediate interdependent associations. TPRs are also 
important for binding to Cdh1 and Cdc20 (Vodermaier et al., 2003). The co-activators 
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use three motifs to interact with the APC/C. These are the C box, KILR (Lys-Iso-Leu-
Arg) motif, and IR (Iso-Arg) motifs. After associating with the APC/C, these co-
activators help the APC/C recognize its substrates through an interaction with the 
substrate’s consensus motif (e.g., D-box: RXXL or KEN box) (Kraft et al., 2005) (Pfleger 
and Kirschner, 2000). While both APC/CCdc20 and APC/CCdh1 recognize the D-box, only 
APC/CCdh1 recognizes the KEN box. APC10/Doc1 has also been reported to enhance the 
APC/C’s substrate binding by forming a substrate recognition co-receptor with Cdh1 
(Buschhorn et al., 2011). In addition, the IR tail of Cdh1 and APC10 both engage with 
APC3. The co-activator binds to the TPR of APC3, and this interaction both facilitates 
substrate recruitment to the APC/C and enhances the specificity of the APC/C (Peters, 
2006) (Thornton et al., 2006) (Matyskiela and Morgan, 2009) (da Fonseca et al., 2011). For 
the APC/C to catalyze substrate ubiquitylation, an E2, either Ubc5 (including Ubc5a, 
Ubc5b and Ubc5c) or UbcH10, is required for initiation, while another E2, UBE2S, 
assembles extended K11-linked polyubiquitin chains on substrates (Wu et al., 2010) 
(Garnett et al., 2009). Mutants of UbcH10 can recapitulate the loss of APC/C activity, but 
UbcH5 mutants cannot. Moreover, depletion of UBE2S has been shown to have a more 
significant effect on ubiquitin chain elongation of APC/C targets than depletion of 
UbcH10 (Peters, 2006) (Wu et al., 2010) (Garnett et al., 2009). 
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1.3.3 Regulation of the APC/C 
The APC/C activity is tightly controlled via  phosphorylation-regulated co-
activator binding, auto-destruction of Cdh1, UbcH10,  and binding of inhibitory proteins 
(Fig. 1.6).    
1.3.3.1 Regulation of co-activators 
Phosphorylation of APC/C subunits by mitotic kinases like Cyclin B/Cdk1 and 
Plk1 increases the affinity of Cdc20 for the core APC/C at M phase. In contrast, 
phosphorylation of Cdh1 by S, G2 and M-Cdks inhibits its association with the APC/C 
(Kraft et al., 2003) (Eckerdt and Strebhardt, 2006). During M phase, APC/CCdc20 targets 
Cyclin B for degradation leading to reduced mitotic Cdk activity; phosphatases 
subsequently increase its dephosphorylation activity.  This temporally -regulated event 
allows Cdh1 dephosphorylation and APC/CCdh1 activation during mitotic exit. In turn, 
APC/CCdh1 marks Cdc20 for destruction, consequently preventing the two co-activators 
from activating APC/C at the same time. Phosphorylation of Cdh1 can also sequester 
Cdh1 to the cytoplasm from the nucleus, and phosphorylated Cdh1 can be targeted by 
SCF for degradation. Therefore, phosphorylation of Cdh1 by Cdks initiates an efficient 
inactivation of the APC/C (Peters, 2006).  
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1.3.3.2 Self-destruction of Cdh1 and UbcH10 
In addition to SCF, Cdh1 has been reported to be ubiquitylated by APC/CCdh1 
itself. The autoregulation of Cdh1 in a feedback loop maintains its lower protein level 
when active, and thus is important for timely inactivation of the APC/C. UbcH10 can 
also trigger its own destruction when there are not many substrates of the APC/C at the 
G1/S transition. This auto-ubiquitylation will attenuate APC/C activity, letting Cyclin A 
accumulate and activate Cdk, which in turn phosphorylates Cdh1 to completely inhibit 
the APC/C (Rape and Kirschner, 2004).      
1.3.3.3 APC/C inhibitors 
Given the pivotal role of timely regulation of the APC/C, there are different 
protein inhibitors acting at different cell cycle stages (Table 1). Emi1 is expressed at the 
G1/S transition and inhibits the APC/C by competing with its substrates for binding, 
suppressing ubiquitin chain elongation, inhibiting ubiquitin transfer, and interrupting 
E2-APC/C association from S to G2 phase. The inhibition of the APC/C by Emi1 prevents 
geminin accumulation and DNA re-replication. When cells enter M phase, Emi1 is 
degraded by SCFβ-TrCP (Wang and Kirschner, 2013) (Di Fiore and Pines, 2007) (Machida 
and Dutta, 2007). 
After cells enter mitosis, Cdk phosphorylates the APC/C and promotes 
APC/CCdc20 assembly to degrade Cyclin A and Nek2A. However, the APC/C is prevented 
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from degrading Cyclin B and securin by the SAC. SAC proteins, including mitotic arrest 
deficient 1 (MAD1), MAD2, budding uninhibited by benzimidazole (BUB)R1, BUB3 and 
MPS1, are recruited to unattached kinetochores to generate the mitotic checkpoint 
protein complex (MCC) with Cdc20 and to inhibit Cdc20 (Fang, 2002) (Eytan et al., 2013). 
The inhibition is partly because BUBR1 can act as a pseudosubstrate inhibitor of Cdc20, 
and also because BUB1 mediates an inactivating phosphorylation on Cdc20 (Burton and 
Solomon, 2007) (Tang et al., 2004). Until the SAC is satisfied (i.e. the chromosomes are 
aligned properly), Cdc20 is auto-ubiquitylated by APC/C and released from the MCC, 
which is dependent on APC15 and APC11 (Mansfeld et al., 2011) (Foster and Morgan, 
2012).   
In addition to these SAC proteins, it has been reported that Ras association 
domain-containing family isoform A (RASSF1A) and RAE-NUP98 can inhibit the early 
mitotic APC/C. RASSF1A is suggested to interact with Cdc20 at prometaphase after 
Emi1 has been degraded, resulting in an inhibition of APC/CCdc20 that is independent of 
the SAC inhibitors and Emi1 (Song et al., 2004). However, a later report suggests that 
Cdc20 does not associate with RASSF1A, and thus the role of RASSF1A is still not clear 
(Liu et al., 2007). While the role of RASSF1A in mitosis remains unsolved, RASSF1A can 
regulate the G1/S transition by restricting Emi1 ubiquitylation by SCF β-TrCP. This 
restriction leads to Emi1 mediated APC/C inhibition (Whitehurst et al., 2008). 
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 Nucleocytoplasmic transport factors Rae1 and Nup98 can form a complex with Cdh1 
and specifically inhibit the ability of APC/CCdh1 to ubiquitylate securin (Jeganathan et al., 
2005). Recently, CUE domain-containing protein 2 (CUEDC2) was reported to inhibit 
Cdh1 by binding to Cdh1 through its KEN box; this inhibition leads to accumulation of 
Cyclin A and G1/S progression (Zhang et al., 2013). Intriguingly, CUEDC2 protein was 
reported to activate Cdc20 by binding with Cdc20 and releasing Cdc20 from MCC 
complex (Gao et al., 2011). 
1.4 Identification of TRIM39 
1.4.1 TRIM39 and Xnf7 
Several years ago, our laboratory reported identification of a novel inhibitor of 
the APC/C in extracts from eggs of Xenopus laevis called Xnf7 (Casaletto et al., 2005).  
Xnf7 is an ~80 kDa protein, which has the ability to bind DNA and is suggested to 
function as a transcription factor, though no Xnf7-target genes have been reported (Li et 
al., 1994; Reddy et al., 1991) (Miller et al., 1991).  Xnf7 contains a cytoplasmic retention 
domain (PRY-SPRY domain), a coiled-coil domain, a nuclear localization sequence, a N-
terminal chromo domain and a RING domain (Beenders et al., 2007).  It can be 
phosphorylated by Cyclin B/Cdk1 and MAPK. Phosphorylation of Xnf7 can change its 
subcellular localization, which in turn affects its ability to regulate the dorsal-ventral 
patterning of the Xenopus embryo. The association of Xnf7 with specific cellular 
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structures (the spindle or centrosomes) is also dependent on its phosphorylation state. 
Xnf7 associates with the mitotic spindle during mitosis and with the centrosomes during 
interphase (Li et al., 1994). It has also been reported to associate with the active 
transcription units of RNA polymerase II during oogenesis and the association requires 
the formation of Xnf7 homotrimerization through its coiled-coil domain (Beenders et al., 
2007). (El-Hodiri et al., 1997a; El-Hodiri et al., 1997b; Li and Etkin, 1993; Miller et al., 
1991; Reddy et al., 1991). Xnf7 depletion leads to hypersensitivity of spindles to 
microtubule-depolymerizing agents. The C-terminus of Xnf7 mediates binding with 
microtubules, which contributes to microtubule organization and spindle integrity 
(Maresca et al., 2005).  
Xnf7 was previously identified as a Cyclin B interacting protein in our 
laboratory. We later found that recombinant Xnf7 can inhibit APC/C mediated 
ubiquitylation in vitro and decrease Cyclin B degradation in Xenopus egg extract. This 
inhibitory ability is dependent on its RING-dependent ligase activity. We also found 
that antibody depletion of Xnf7 can override SAC signaling, permitting Cyclin B 
degradation (Casaletto et al., 2005).  
 In searching for a human homolog of the Xenopus Xnf7 protein, we identified 
two proteins, TRIM39 and TRIM69, that share 42% and 46% sequence homology to Xnf7, 
respectively. In this thesis, I describe our in depth characterization of Trim 39 function. 
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1.4.2 TRIM39 function 
TRIM39 was initially cloned from a human testis cDNA library in 2000. The 
cDNA produces a 518-amino acid protein and shares 98% identity with the mouse 
TRIM39 sequence. The gene is mapped to the class I region of the human MHC (major 
histocompatibility complex) on chromosome 6. Northern blotting showed that the gene 
is ubiquitously expressed, with strong expression in the testis, skeletal muscle and 
spleen (Orimo et al., 2000).  Alternate splicing results in two transcript variants encoding 
different isoforms: 518 amino acids (isoform 1) or 488 amino acids (isoform 2). Isoform 2 
lacks exon 7 when compared to isoform 1. Of note, we used isoform 2 for all 
overexpression and protein purification experiments in the dissertation whereas our 
shRNA can target both isoforms. Later in 2007, Robert et al. cloned a splice variant 
cDNA (TRIM39R) which contains the COOH-terminal portion of Rpp21, a component of 
RNase P (Roberts et al., 2007). The TRIM39R cDNA product was found to interact with 
cGMP-dependent protein kinase I (PKGI) by the yeast two-hybrid method. This group 
also reported that both TRIM39 and TRIM39R can interact with PKGI. However, the 
function of these interactions is still unclear (Fig. 1.7).   
TRIM39 belongs to the Tripartite Motif (TRIM) family and contains a RING 
domain, two B-boxes, a coiled-coil domain and a PRY-SPRY domain. The RING motif is 
a linear sequence of conserved cysteine and histidine residues that can bind two zinc 
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ions in a manner similar to a zinc finger motif. The B-box also possesses a zinc ion 
binding ability, and the coiled-coil domain can mediate homomeric or heteromeric 
interactions with other proteins. Most TRIM proteins play a role in post-translational 
modification; such modifications include: ubiquitylation, sumoylation (small ubiquitin 
modifier), and ISGylation (interferon (IFN)-induced 15-kDa protein encoded by IFN-
stimulated gene 15). They have been reported to be involved in tumor formation, 
apoptosis, immune responses, and transcriptional regulation (Ikeda and Inoue, 2012). 
For example, TRIM19, TRIM24, TRIM25, and TRIM27 have been linked to tumor 
initiation and progression. Mutation of several TRIM family genes has been found to 
lead to disease formation. For example, mutations in TRIM18 are associated with X-
linked Optiz G/BBB syndrome; mutations in TRIM20 are linked to familial 
Mediterranean fever; mutations in TRIM37 are related to mulibrey nanism and 
mutations in TRIM32 are connected to limb girdle muscular dystrophy type 2H (Ryu et 
al., 2011) 
There are few studies regarding the function of TRIM39. TRIM39 has been 
suggested to be associated with Behçet’s disease as the presence of a single nucleotide 
polymorphism (SNP) located on exon 9 of TRIM39 occurs with disease development 
(Kurata et al., 2010).  Another study suggests a role for TRIM39 in apoptosis. Using the 
yeast two-hybrid method, TRIM39 was found to interact with modulator of apoptosis 1 
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(MOAP-1). MOAP-1 protein was previously identified as a Bcl-2-associated protein X 
(Bax) interactor, and MOAP-1 can facilitate Bax activation to promote apoptosis (Tan et 
al., 2005).  When TRIM39 is overexpressed, its interaction with MOAP-1 stabilizes 
MOAP-1 levels and enhances etoposide-induced Bax-mediated apoptosis.  Accordingly, 
TRIM39 knockdown dampens cell death following etoposide treatment. These findings 
suggest that TRIM39 enhances MOAP-1 protein stabilization, possibly by inhibiting the 
regulator(s) of MOAP-1 (Lee et al., 2009).  
1.5 Apoptosis 
Apoptosis is an elaborate mechanism that serves to maintain cell homeostasis.  It 
is important for development and multi-cellular function since it can eliminate cells that 
are potentially detrimental to the organism or cells that are inactive in a specific 
development stage. Misregulation of apoptosis is involved in both cancer progression 
and neurodegeneration. Apoptosis is characterized by fragmented chromatin, reduced 
cell volume and cell membrane blebbing, which exposes phosphotidylserine. This 
phospholipid will attract macrophages to execute phagocytosis of the cells, thereby 
preventing the release of cellular contents which might otherwise damage surrounding 
cells.  (Afford and Randhawa, 2000; Kerr et al., 1972) (Elmore, 2007; Martin et al., 1995). 
Apoptosis is executed by a subset of cysteine dependent aspartate-directed 
proteases known as caspases. In healthy cells, caspases are translated as inactive 
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zymogens which are activated via proteolytic cleavage and/or oligomerization upon 
receiving a death stimulus. There are two classes of caspases: initiator caspases (caspase-
8, 10, 9, 2) and effector caspases (caspase-3, 7, 6.) Initiator caspases automatically activate 
when they interact with adaptor proteins after receiving pro-death signals. These 
activated initiator caspases go on to relay these signals to effector caspases, which 
consequently become activated through proteolytic cleavage. These activated effector 
caspases will go on to cleave their substrates, thus promoting apoptosis (Fuentes-Prior 
and Salvesen, 2004; Kumar, 2007; Nicholson and Thornberry, 1997; Nunez et al., 1998; 
Stennicke and Salvesen, 1998). 
1.5.1 Apoptosis pathways 
Initiator caspases can be activated by either an extrinsic or intrinsic pathway (Fig. 
1.8). The extrinsic pathway is initiated when an extracellular ligand such as Fas, tumor 
necrosis factor a (TNF-α), or TNF related apoptosis inducing ligand (TRAIL) binds to its 
specific receptor, leading to activation of caspase-8 or caspase-10.  After the ligands bind 
the Cys rich extracellular subdomains of these receptors, the receptors will subsequently 
trimerize and activate. Subsequent signaling is mediated by the death domain (DD) 
containing cytoplasmic part of the death receptor. This DD domain interacts with a DD 
domain on an adapter molecule like Fas-associated death domain protein (FADD) or 
Tumor necrosis factor receptor type 1-associated DEATH domain (TRADD) to form the 
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death inducing signaling complex (DISC). The death effector domain (DED) of FADD 
will then recruit procaspase-8 or procaspase-10 to the DISC to facilitate activation of 
caspase-8 or caspase-10. The initiator caspases can then go on to directly cleave and 
activate caspase-3, which in turn mediate the proteolytic cleavage of various substrates 
and ultimately cell death. Caspase-8 can also cleave Bid (t-Bid) and engage the intrinsic 
pathway to induce apoptosis efficiently (Ashkenazi and Dixit, 1998; Danial and 
Korsmeyer, 2004; Kischkel et al., 2000; Kischkel et al., 2001) (Fulda and Debatin, 2006) 
(Wajant, 2002) (Wang and El-Deiry, 2003) (Slee et al., 1999).  
The intrinsic pathway senses intracellular stresses, such as DNA damage, 
oxidative stress, and nutrient deprivation, and is mediated by the B cell lymphoma 2 
(Bcl-2) protein family. These proteins control mitochondrial outer membrane 
permeabilization (MOMP) and cytochrome c release (Waterhouse and Green, 1999). 
Cytochrome c then binds Apaf-1 to assemble the apoptosome wherein caspase-9 
becomes activated (Li et al., 1997; Srinivasula et al., 1998). Caspase-9 then activates the 
downstream effector caspases, caspase-3, -7, and -6. Besides caspase-9, caspase-2 is also 
considered to be an initiator caspase in response to certain apoptotic stimuli, including 
heat shock, DNA damage, nutrient deprivation and ER stress (Krumschnabel et al., 
2009). It has been reported that the “PIDDosome”, which contains the p53-Induced 
protein with a Death Domain (PIDD) and an adaptor protein, the RIP-associated 
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ICH-1/CED3 homologous protein with a Death Domain (RAIDD), mediates caspase-2 
dimerization and activation in response to DNA damage. Once activated, caspase-2 will 
cleave Bid (t-Bid) and t-Bid will then promote cytochrome c release (Janssens and Tinel, 
2012).  
1.5.2 Bcl-2 family and apoptosis 
As mentioned previously, Bcl-2 family proteins are critical regulators of 
cytochrome c release and therefore control the balance between cellular life and death. 
This balance is influenced by the interaction between pro-apoptotic (e.g., Bax, Bak, or the 
Bcl-2 homology domain 3 (BH3)-only proteins Bid, Bim, Bad, or PUMA) and anti-
apoptotic (Mcl-1, Bcl-2, or Bcl-xl) Bcl-2 family proteins (Kelekar and Thompson, 1998) 
(Adams and Cory, 2007) (Fig. 1.9). The anti-apoptotic proteins promote cell survival by 
binding through BH domains and blocking the function of pro-apoptotic proteins. BH3-
only proteins promote apoptosis by either activating Bax/Bak or neutralizing anti-
apoptotic proteins from sequestering Bax/Bak (Westphal et al., 2011) (Kelekar et al., 1997; 
Korsmeyer, 1999; Wang et al., 1996).  
Bax and Bak are direct regulators of MOMP; they can translocate and insert into 
the mitochondrial outer membrane, oligomerize, and form pores. Bak is constitutively 
located at mitochondria whereas Bax is shuttled between the cytosol and mitochondria 
as a monomer. Upon apoptotic stimulation, Bid, Bim, and PUMA induce a 
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conformational change in Bax, allowing it to target the mitochondria and form 
oligomers, thereby enabling cytochrome c release (Kim et al., 2009) (Westphal et al., 
2011) (Walensky and Gavathiotis, 2011).  
MOAP-1 protein is reported to bind Bax through an interaction between MOAP-
1’s BH3 like domain and all three BH domains of Bax upon apoptotic stimuli. When it is 
overexpressed, it can trigger apoptosis (Tan et al., 2001.) When it is knocked down, 
either the intrinsic or extrinsic apoptosis pathways are compromised. MOAP-1 facilitates 
Bax- and tBid-mediated release of cytochrome c from isolated mitochondria (Tan et al., 
2005). Moreover, it has been reported to cooperate with RASSF1A to activate Bax in 
response to activated K-Ras, TNF-alpha, or TRAIL stimulation (Foley et al., 2008; Vos et 
al., 2006). Under healthy conditions MOAP-1 is a short–lived protein, but its stability is 
increased upon intrinsic or intrinsic apoptotic stimulation (Fu et al., 2007).  
1.6 p53 
The tumor suppressor p53 was discovered in 1979 as a 53 kD protein that 
interacts with the SV40 large T antigen (Linzer and Levine, 1979). p53 is a crucial 
transcription factor that governs many biological activities such as cell cycle arrest, 
senescence, apoptosis, DNA damage responses, and metabolism. The importance of p53 
can be demonstrated by the fact that nearly 50% of cancers contain TP53 (which encodes 
p53) inactivating mutations (Wade et al., 2010). In other cancers, TP53 is not mutated but 
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instead is silenced by deregulation of the p53 signal transduction pathway (Zuckerman 
et al., 2009). Accordingly, p53-/- mice develop tumors within 6 months after birth and 
p53+/- mice are also prone to form tumors, although more slowly. (Fuster et al., 
2007).(Donehower et al., 1992)    
1.6.1 The function of p53 
p53 is an inactive and unstable protein under normal physiological conditions; 
however, it can be stabilized and induce a stress response following specific stimuli, 
including direct DNA damage, exposure to mitotic spindle toxic chemicals, hypoxia, 
oncogenic signaling, ribonucleotide depletion, and exposure to nitric oxide (Pluquet and 
Hainaut, 2001). Typically, these processes are attributed to transcriptional activity of 
nuclear p53. For example, p53 up-regulates cell cycle arrest-related genes such as p21 
and 14-3-3σ, or it promotes pro-apoptotic genes including Bax, Bak and PUMA.  In 
addition, p53 can enhance autophagy by induction of DRAM and Sestrin2. p53 can also 
inhibit glucose metabolism via up-regulation of TP53-induced glycolysis 
and apoptosis regulator (TIGAR) expression.(Vogelstein et al., 2000) (Yu et al., 2001) 
(Reinhardt and Schumacher, 2012) (Giono and Manfredi, 2006; Levine and Abrams, 
2008) 
  However, there is increasing evidence suggesting that cytosolic p53 also plays a 
non-gemonic role in apoptosis. Cytosolic p53 can translocate to the mitochondrial outer 
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membrane and promote Bax/Bak activation through interaction with Bcl-2 and Bcl-xl. 
p53 has also been reported to interfere with the interaction between Bak and Mcl-2 by 
directly associating with Bak. There are also reports suggesting that mitochondrial p53 
interacts with Bak and Bad to induce apoptosis. Moreover, cytosolic p53 has been shown 
to inhibit autophagy, probably though mechanisms related to LC3 or HMGB1 proteins. 
(Marchenko et al., 2000) (Mihara et al., 2003) (Chipuk et al., 2004) (Jiang et al., 2006) 
(Scherz-Shouval et al., 2010; Tasdemir et al., 2008)  (Livesey et al., 2012) Figure 1.10 
summarizes the role of p53 in cell cycle arrest and apoptosis.  
1.6.2 Post-translational regulation of p53 
Besides localization, p53 function and activity are regulated by post-translational 
modification. Post-translational modifications on different residues coordinately affect 
the interactors, stability, and target genes of p53, and many of these sites are conserved. 
Potential modifications of these sites include phosphorylation, acetylation, 
ubiquitylation, sumoylation, neddylation and methylation. These modifications of p53 
vary in different cell lines and under various conditions, providing complex and 
intricate layers of p53 regulation.   
Human p53 consists of five functional domains (Fig. 1.11). The N-terminal 
transactivation domain (TAD) is required for activation of transcription. Close to the 
transactivation domain is the proline-rich domain (PRD), which mediates protein-
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protein interactions and regulates p53 stability. The DNA binding domain is central in 
the p53 molecule and binds to specific promoters of target genes; most mutations of p53 
are found in this domain (Bode and Dong, 2004). The C-terminus of p53 consists of the 
tetramerization and the C-terminal regulatory domains. In cells without stress, p53 is 
inactive and maintained at low levels because MDM2 prevents transcription factors 
from binding to TAD and promotes p53 ubiquitylation and degradation (Toledo and 
Wahl, 2006 {Walker, 1996 #27) (Zhu et al., 1998) (Chang et al., 1995). Stress signals induce 
phosphorylation of p53 TAD and PRD domains (Ser-15, 20 and Thr 18). These 
modifications reduce MDM2 binding, thus stabilizing p53 and promoting p53 
tetramerization. Tetramerization of 53 leads to higher nuclear retention and full 
transcriptional activity(Stommel et al., 1999) (Honda et al., 1997). Phosphorylation of 
these sites could also promote recruitment of more transcriptional co-activators.   
As mentioned above, most phosphorylation modifications on p53 enhance its 
transcriptional activity; interestingly, some modifiable sites (ser-215, 376 and Thr-55) are 
constitutively phosphorylated and inhibit either transcriptional activity or DNA binding 
of p53 in unstressed cells. Moreover, other phosphorylation events can determine the 
function of p53. For instance, phosphorylation of Ser-46 mediates p53-dependent pro-
apoptotic gene induction, but does not enhance expression of genes related to cell cycle 
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arrest (Stavridi et al., 2001) (Dai and Gu, 2010; Liu et al., 2004; Olsson et al., 2007; Taira et 
al., 2007).  
Acetyl modifications can also affect p53 specificity for targeted genes in addition 
to stabilization of p53 by competing with ubiquitin for Lys sites. Lys-64 acetylation of 
p53 promotes the expression of genes involved in cell cycle arrest, such p21 (Knights et 
al., 2006). Lys-120 acetylation has been suggested to mediate p53-activated pro-apoptotic 
genes instead of cell cycle related genes. Additionally, this acetylation is required for 
p53-mediated dissociation of Bak and Mcl-2 to promote apoptosis (Sykes et al., 2006; 
Sykes et al., 2009).   
1.6.3 Ubiquitin ligase of p53 
The amount of p53 protein within a cell is strictly controlled by the ubiquitin-
proteasome system to ensure proper cell proliferation and viability. As described 
previously, the RING-domain containing protein MDM2 is the major E3 ligase for p53. 
MDM2 mediates poly-ubiquitylation of p53 when the MDM2 level is high and mediates 
mono-ubiquitylation of p53 as a nuclear export signal when MDM2 is low (Li et al., 
2003). Embryonic lethality in MDM2 null mice can be rescued by p53 knockout, 
indicating the importance of MDM2 in regulating p53 (Brooks and Gu, 2006; Jones et al., 
1995; Montes de Oca Luna et al., 1995). Interestingly, MDM2 is also a transcriptional 
target of p53, thereby forming a negative feedback loop to regulate p53 activity. This 
  
30
regulatory complexity is extensive as MDM2 can also autoubiquitylate, and the decision 
whether to target p53 or itself is influenced by ARF, which sequesters MDM2 away from 
p53 (Buschmann et al., 2000; Kubbutat et al., 1997; Pomerantz et al., 1998; Zhang et al., 
1998). Moreover, CBP/p300 mediated-acetylation of MDM2 has been reported to reduce 
interaction between MDM2 and p53, and thus promotes p53 accumulation (Wang et al., 
2004).  
There are several other ubiquitin E3 ligases that can target p53. PIRH2, COP, 
CHIP, CARP1, CARP2, ARF-BP1, TRIM24, Synoviolin and Topors can polyubiquitylate 
p53, targeting it for degradation (Love and Grossman, 2012). In contrast, male-specific 
lethal-2 (Msl2) polyubiquitylates p53, but this ubiquitylation promotes its nuclear export 
instead of its degradation. WW domain-containing protein 1 (WWP1) E3 ligase can also 
ubiquitylate p53 and this modification changes the localization and stability of p53 by 
preventing MDM2-mediated p53 ubiquitylation. Similarly, Ubc13, an E2 conjugating 
enzyme, induces Lys63 polyubiquitylation on p53 to disrupt the interaction between p53 
and MDM2. Moreover, this Lys63 ubiquitylation also signals nuclear export, decreases 
transcriptional activity, and reduces tetramerization of p53 (Brooks and Gu, 2011; Love 
and Grossman, 2012).  Surprisingly, the transcription factor E4F1 behaves as an atypical 
E3 ligase (without RING or HECT domain) and polyubiquitylates p53, increasing the 
chromatin association of p53. This association regulates p53-dependent cell cycle arrest, 
  
31
further demonstrating that post-translation modifications modulate the function of p53 
(Le Cam et al., 2006).  In this thesis, I describe the p53-ubiquitylating activity of TRIM39.  
Table 2 summarizes all the reported E3 ligases of p53. 
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Table 1. APC/C Inhibitors 
Inhibitor  Species  Proposed to inhibit  Proposed mechanism  
Cdk1  Sc, Sp, Hs APC/C
Cdh1
 in S and G2 Cdh1 phosphorylation 
Cdk1 Xl APC/C
Cdc20
 in prometaphase Cdc20 phosphorylation and 
interaction with Mad2 
APC/C
Cdh1
 Hs, Sc  APC/C
Cdc20
 in anaphase  Cdc20 degradation  
SCF  Hs  APC/C
Cdh1
 in S phase  Cdh1 degradation  
Mad2  Sc, Hs  APC/C
Cdc20
 in prometaphase  Inhibition of Cdc20 substrate 
release  
Mad2B  Xl, Hs  APC/C
Cdh1 
 Inhibition of Cdh1 substrate 
release  
BubR1  Hs  APC/C
Cdc20
 in prometaphase  Cdc20 sequestration  
Bub1  Hs  APC/C
Cdc20
 in prometaphase  Cdc20 phosphorylation  
MAPK  Xl  APC/C
Cdc20
 in prometaphase  Cdc20 phosphorylation  
Emi1  Xl, Hs  APC/C
Cdch1
 in S and G2 
phases  
Substrate binding competition, 
inhibition of ubiquitin chain 
elongation, inhibiting ubiquitin 
transfer and interrupting E2-E3 
association. 
Rca1  Dm  APC/C
Cdc20
 in S and G2 
phases  
Unknown  
Emi2  Xl, Hs  APC/C
Cdc20
 in meiosis II  Inhibiting ubiquitin transfer from 
E2 to substrate 
Acm1 Sc APC/C
Cdh1
 in S and G2 Unknown. Forms complex with 
yeast 14-3-3 homologs (Bmh1/2) 
Mes1  Sp  APC/C
Cdc20
 during meiosis 
exit  
Substrate binding competition  
Mnd2  Sc  APC/C
Ama1
 in meiosis I  Unknown  
Rassf1A  Hs  APC/C
Cdc20
 in mitosis  Cdc20 binding  
Xnf7  Xl  APC/C
Cdc20
 in mitosis  Unknown, ligase activity required  
RAE1-
NUP98  
Mm  APC/C
Cdc20
 in prometaphase  Interaction with Cdh1 
Apoptin  CAV   APC/C
Cdh1
  APC1 binding  
Unknown  HCMV  APC/C
Cdh1
 in G0 phase  Inhibition of APC/C and Cdh1 
interaction  
CUEDC2 Hs APC/C
Cdh1
 Substrate binding competition  
E4orf4  HAV  APC/C
Cdc20
  PP2A recruitment  
TRIM39 Hs APC/C
Cdc20
  and APC/C
Cdh1
 in 
vitro 
Unknown, ligase activity required 
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Mad2B is also known as MAD2L1. CAV, chicken anemia virus. Dm, Drosophila melanogaster. HAV, human 
adenovirus. HCMV, human cytomegalovirus. Hs, homo sapiens. MAP, mitogen-activated protein. Mm, Mus 
musculus. Mnd2, meiotic nuclear division protein-2. RAE1, Rab escort protein-1. RCA1, regulator of Cyclin 
A-1. Sc, Saccharomyces cerevisiae. Sp, Schizosaccharomyces pombe. Xl, Xenopus laevis. Xnf7, Xenopus nuclear 
factor 7. (Adapted and modified from  (Peters, 2006) ) 
 
Table 2. E3 Ubiquitin Ligase of p53 
              
Adapted from (Love and Grossman, 2012) 
E3 ligase E3 domain impact on p53 
MDM2 RING Degradation, export, transcription 
Pirh2 RING Degradation, tetramerization 
ARF-BP1 HECT Degradation 
E4F1 ?? Transcription 
CHIP U box Degradation 
TRIM24 RING Degradation, export, transcription 
Cul1/Skp2 RING Degradation 
Cul4a/DDB1/Roc RING Degradation 
Cul5 RING Degradation 
Cul7 RING Export, transcription 
Msl2 RING Export 
WWP1 HECT Export, transcription, protein 
accumulation 
Synoviolin RING Degradation, export, transcription 
TOPORS RING Degradation,transcription 
Cop1 RING Degradation,transcription 
CARP1/2 RING Degradation 
Ubc13 ?? Export, transcription, tetramerization 
TRIM39 RING Degradation 
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Cyclin D-CDK4/6
CDK inhibitors: p21, 
p27, p16, p19…etc
 
Figure 1. 1: The cell cycle.  
Figure 1.1: Cell cycle is dived by G1, S, G2 and mitosis phases. Each phase is controlled 
by Cyclin/Cyclin-dependent kinase (Cdk) complex. Cdk activity can be modulated by 
various inhibitors such as p21, p27, p16 and p19. Figure is adapted and modified from 
(Pines, 2011).  
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Figure 1. 2 Ubiquitin proteasome pathway. 
Figure 1.2: Ubiquitylation is activated by E1 activating enzyme which utilizes ATP to 
form a thioester linkage between ubiquitin (U) and Cys on E1. E2 conjugating enzyme 
catalyzes the transfer of ubiquitin from E1 to Cys of E2. E3 ligase functions as substrate 
recognition molecule and interacts with both substrate and E2 to catalyze the transfer of 
ubiquitin. One cascade adds one ubiquitin molecule on the substrate and after several 
rounds,  polyubiquitylation will mark the substrate to 26S proteasome for destruction. 
(modified from (Wasch and Engelbert, 2005)) 
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Figure 1. 3: DNA damage response.  
Figure 1.3: A schematic diagram of DNA damage response. Green lines indicate 
activation. Red lines indicate inhibition by phosphorylation or by ubiquitin-proteasome 
system. Encircled p indicates phosphorylation. NHEJ: non-homologous end joining.  
(Modified from (Harper and Elledge, 2007) 
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Figure 1. 4: APC/C components and structure. 
Figure 1.4: Left: Different choices of co-activator, E2 conjugation enzyme and substrate 
motif of APC/C complex. Right: diagram cartoon represent the structure of APC/CCdh1 
complex resolved from cryo-EM map. The light gray molecular composes TPR domain 
containing subunit. Colorful molecular constitutes substrate docking site and enzyme 
activity site. This diagram is modified from (Schreiber et al., 2011.) 
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Figure 1. 5: APC/C regulates cell cycle. 
Figure 1.5: The substrates of APC/C in different cell cycle stages. APC/CCdc20 is active 
during mitosis where it controls the proper attachment of chromosomes on 
microtubules. APC/CCdh1 is active from anaphase to G1 phase. For details, please read 
the text.   
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Figure 1. 6: Rugulation of APC/C activity. 
Figure 1.6: APC/C activity is controlled by different means: phosphorylation, self-
destruction and inhibitors. Each control is important for the timely activation of APC/C. 
Red box represents inhibition on APC/C; Green box represents activation on APC/C.   
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Figure 1. 7: The genome structure of TRIM39, TRIM39R, and Rpp21. 
Figure 1.7: TRIM39 gene has three variants: two isoforms of TRIM39 full length and one 
fused with part of Rpp21 gene. One separate rectangle indicates an exon of transcripts.   
(Adapted from (Kurata et al., 2013)) 
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Figure 1. 8: Extrinsic and intrinsic apoptosis pathways.  
Figure 1.8: Apoptosis can be initiated by extrinsic or intrinsic pathway. The extrinsic 
pathway is activated by death receptor to activate caspase-8. Intrinsic pathway includes 
PIDDosome activated caspase-2 or Bcl-2 family protein regulated cytochrome c release. 
Both pathways will activate caspase-9 through apoptsome and activate executor caspase.  
Adapted from (Kurokawa and Kornbluth, 2009) 
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Figure 1. 9: Bcl-2 family proteins.  
Figure 1.9: Bcl-2 family is divided by their roles in apoptotic promotion or anti-apoptotic 
function. They also can be divided by the number of BH (Bcl-2 homology) domain. TM: 
transmembrane domain. Modified from (Zimmermann et al., 2001).  
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Figure 1. 10: p53 function in cell cycle and apoptosis.  
Figure 1.10: p53 can modulate cell cycle and apoptosis through transcription activation 
or repression. p53 can also affect apoptosis by interacting with Bcl-2 family proteins. 
(Modified from (Zuckerman et al., 2009)) 
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Figure 1. 11: Functional domain of 53. 
Figure 1.11: p53 is a 393 aminio acids length protein and has five functional domains. N-
terminal transactivation domain (TAD) is required for transcription activation. Proline-
rich domain (PRD) mediates protein-protein interactions and regulates p53 stability. 
DNA binding domains is involved in protein interaction and this region is regulated by 
C-termial regulatory domain (CRD). Tetramerization domain (TetraD) mediates self-
association of p53 and forms tetramer of p53 which can enhance transcription regulatory 
activity.  
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2. APC/CCdh1-mediated degradation of the Bax activator 
MOAP-1 controlled by the TRIM39 ubiquitin ligase 
This chapter is adapted from (Huang et al., 2012) 
2.1 Summary 
Pro-apoptotic Bcl-2 family members, such as Bax, promote release of cytochrome 
c from mitochondria, leading to caspase activation and cell death. It was reported that 
MOAP-1, an enhancer of Bax activation induced by DNA damage, is stabilized by 
TRIM39, a protein of unknown function. In the chapter, we show that MOAP-1 is a 
novel substrate of the anaphase promoting complex (APC/CCdh1) ubiquitin ligase and 
that the influence of TRIM39 on MOAP-1 levels stems from the ability of TRIM39 (a 
RING domain E3 ligase) to directly inhibit APC/CCdh1-mediated protein ubiquitylation. 
Accordingly, siRNA-mediated knockdown of Cdh1 stabilized MOAP-1, thereby 
enhancing etoposide-induced Bax activation and apoptosis. These data identify TRIM39 
as a novel APC/C regulator and provide an unexpected link between the APC/C and 
apoptotic regulation via MOAP-1. 
2.2 Introduction 
Apoptosis is critical for proper embryonic development, the response to cellular 
damage and overall organismal homeostasis. In the intrinsic apoptotic pathway, cell 
death stimuli promote release of mitochondrial cytochrome c to the cytoplasm, where it 
binds Apaf-1 to promote activation of the cell death protease. 
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Mitochondrial cytochrome c release is governed by Bcl-2 family proteins, 
including Bax and Bak, that trigger cytochrome c release through oligomerization at the 
mitochondrial outer membrane (Antonsson and Martinou, 2000; Eskes et al., 2000).  
Apoptotic signaling induces a conformational change in Bax and translocation to 
mitochondria where it can affect outer membrane permeabilization (Antonsson, 2001; 
Antonsson et al., 2001).    
Modulator of Apoptosis-1 (MOAP-1, originally termed MAP-1) is a Bax-
interacting protein whose knockdown inhibits apoptosis triggered by various stimuli 
(Tan et al., 2001). MOAP-1 association with Bax promotes Bax mitochondrial 
translocation and activation (Tan et al., 2005; Vos et al., 2006). Under non-apoptotic 
conditions, MOAP-1 undergoes constitutive degradation by the ubiquitin proteasome 
system, though the E3 ubiquitin ligase responsible for MOAP-1 ubiquitylation is 
unknown. Following receipt of certain cell death stimuli, MOAP-1 degradation is 
inhibited by TRIM39(Orimo et al., 2000). Therefore, TRIM39 overexpression enhances 
etoposide-induced Bax-mediated apoptosis through stabilization of MOAP-1, while 
TRIM39 knockdown dampens cell death following etoposide treatment (Fu et al., 2007; 
Lee et al., 2009).  
TRIM39 contains a RING domain, a B-box and a coiled-coil domain (Deshaies 
and Joazeiro, 2009).  For a number of TRIM family members, the RING domain confers 
E3 ubiquitin ligase activity. However, since TRIM39 promotes MOAP-1 stabilization, 
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rather than degradation, it is clearly not directly responsible for MOAP-1 degradation. 
Rather, TRIM39 must in some way negatively regulate a MOAP-1-directed E3 ligase.    
Analysis of TRIM39’s primary sequence revealed it to be the closest mammalian 
homolog of a previously identified E3 ligase from Xenopus laevis known as Xnf7 
(Casaletto et al., 2005).   Xnf7 has several biological activities, including regulation of 
mitotic exit through its ability to inhibit the APC/C (Casaletto et al., 2005).   
The APC/C is a multi-subunit E3 ubiquitin ligase that associates with one of two 
activators, Cdh1 or Cdc20.  These activators mediate substrate recognition through 
consensus motifs present on substrates (e.g., the destruction box, RXXLXXXXN/D/E) 
(Pfleger and Kirschner, 2000). Cyclin A and Cyclin B1 ubiquitylation in M phase are 
mediated by the APC/CCdc20; in contrast, Cdh1 modulates the APC/C activity from M 
phase exit to G1, ubiquitylating Cdc20, Cyclin B1 and Geminin.  The APC/C also 
controls degradation of a handful of other substrates involved in DNA replication, 
glycolysis and mitochondrial dynamics (Colombo et al., 2010; Sugimoto et al., 2008) 
Here, we identify MOAP-1 as a novel APC/CCdh1 substrate.  MOAP-1 is degraded 
after anaphase by APC/CCdh1 and this degradation is inhibited by TRIM39 acting on the 
APC/C.  TRIM39 E3 ubiquitin ligase activity is required to block MOAP-1 (and other 
APC/C substrate) destruction.   Furthermore, enhanced apoptosis following Cdh1 
knockdown depends in part on MOAP-1. Thus, these data link the APC/C and apoptosis 
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and explain the previously reported connection between TRIM39 and the Bax activator, 
MOAP-1.  
2.3 Material and method 
2.3.1 Plasmids and protein preparation 
HA-Cdh1 and Myc-MOAP-1 plasmids were kind gifts from M. Pagano (NYU) 
and V. C. Yu (IMCB, Singapore.) Recombinant maltose binding protein (MBP) fused to 
MOAP-1 was cloned from the pXJ40-Myc MOAP-1 plasmid into BamHI and SalI sites in 
the pMal vector and expressed in BL21 bacteria. MBP-TRIM39 was prepared from a 
construct purchased from ATCC. MOAP-1 mutants were prepared using QuikChange 
Site-Directed Mutagenesis Kits (Stratagene). In vitro translated 35S-labeled MOAP-1, 
Cyclin B1, Geminin proteins were generated by using the TNT quick-coupled 
transcription/translation system (Promega). 
2.3.2 Cell culture and synchronization 
HeLa and HEK 293T cells were grown in DMEM with 10% fetal bovine serum at 
37 ºC. PC3 cells were grown in F12K medium. For nocodazole synchronization 
experiments, HeLa cells were double thymidine blocked using 2.5 mM thymidine and 
released into medium containing 100 ng/ml nocodazole after PBS washing for 16 h. To 
prepare cell extracts at different cell cycle stages, prometaphase cells were collected by 
shake-off, followed by washing with PBS and releasing into DMEM media for 0 h, 1 h or 
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4 h. The cells were lysed in hypotonic buffer (20 mM Hepes, pH7.7, 5 mM KCl, 1.5 mM 
MgCl2, 1 mM DTT) on ice and released into the cell cycle at room temperature. 
2.3.3 Transfection and siRNA 
Fugene 6 (Roche) was used to transfect cells with plasmids according to the 
manufacturer’s instructions. Lipofectamine RNAiMax (Invitrogen) was used to perform 
siRNA transfections. siRNA ON-TARGET plus SMARTpool targeted MOAP-1, TRIM39 
were purchased from Dharmacon. Cdh1 siRNA (5'-GGAACACGCUGACAGGACA-3') 
was based on a previously reported effective sequence and purchased from Dharmacon 
(Song et al., 2011). siRNA directed against a non-mammalian protein, firefly luciferase 
(5'-CGUACGCGGAAUACUUCGA-3'), was used as the control siRNA.  
2.3.4 Antibodies and immunoprecipitation 
The following antibodies were used in this study: anti-CyclinB1, anti-HA, anti-
Myc, anti-Actin and anti-Cdc27 (APC3) (Santa Cruz Biotechnology), anti-MBP (Abcam), 
anti-MOAP-1 (Sigma), anti-Bax (N20), anti-Bax (6a7) (BD Bioscience), anti-Cdh1 
(Abcam), anti-caspase 3 (Cell Signaling). 
Cells were lysed with EB buffer (20 mM Hepes (pH 7.4), 150 mM NaCl, 12.5 mM 
β-glycophosphate, 1.5 mM MgCl2, 2 mM EGTA, 10 mM NaF, 2 mM DTT, 1 mM Na3VO4, 
1 mM PMSF, 20 uM aprotinin and 0.5% triton X100) and extracts containing equal 
amounts of proteins were incubated with HA antibody (1ug) and protein A sepharose 
beads overnight at 4 ºC. After washing three times in IP buffer (50 mM Tris (pH 7.5), 150 
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mM NaCl, 1 mM EGTA, 1mM EDTA, 1% Triton X-100 and 0.1% NP-40) and two times 
with  IP buffer plus 150 mM NaCl and 0.02% triton X-100, samples were resolved by 
SDS-PAGE for immunoblotting.  
2.3.5 TRIM39 in vitro ubiquitylation 
0.25 µM recombinant MBP-TRIM39 WT, C44A and C52A were separately 
incubated with 12.5 nM E1 and 250 nM E2 (UbcH5c or other E2s as indicated) and 10 µM 
ATP at 30 ºC for 1 h. For TRIM39 truncated mutant E3 ligase activity assay, 0.25 µM 
recombinant MBP, MBP-TRIM39 WT, C44A and 1-104, and 1-336 were individually 
incubated with in vitro translated 35S-labeled TRIM39 C44A, 12.5 nM E1 and 250 nM E2 
(UbcH5c) and 10 µM ATP at 30 ºC for 1 h. 
2.3.6 APC/C assay 
The APC/C assay was performed as previously described (Tang et al., 2010). 
APC/C was precipitated using Cdc27 (APC3) antibody from M or G1 phase HeLa cells 
and then incubated with in vitro translated 35S-labeled proteins, 240 µM ubiquitin, 12.5 
nM E1 and 250 nM E2 (UbcH5a, UbcH5c, UbcH10 or Ube2S as indicated), 10 µM ATP 
and 2.25 µM His-Cdh1 at 30 ºC for 1 h. In some experiments, more than two E2s are 
added (each concentration is 250 nM) therefore the total E2 concentration is increased. 
2.3.7 Pull down assay 
2 µg of MBP (0.25 µM), MBP-MOAP-1 WT or D-box MT (0.1 µM) were incubated 
with 0.75 µg of His-Cdh1 in total volume 200 µl IP buffer (50 mM Tris (pH 7.5), 150 mM 
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NaCl, 1 mM EGTA, 1mM EDTA, 1% Triton X100 and 0.1% NP-40) for 2 h at 4ºC. 
Amylose beads were added for another 1 h to pull down His-Cdh1, and washed five 
times with IP buffer.  Samples were analyzed by immunoblotting. 
2.3.8 Flow cytometry assay 
Cells were trypsinized and washed with PBS. For sub-G1 analysis, cells were 
fixed with 70% ethanol in PBS in -20 ºC overnight and stained with Propidium iodide 
(PI) for flow cytometry analysis. 
2.4 Results 
2.4.1 TRIM39 is an Xnf7-related E3 ubiquitin ligase 
Previous work from our laboratory identified Xnf7 as a RING-domain containing 
E3 ligase and APC/C inhibitor in Xenopus laevis (Casaletto et al., 2005). In a blast search 
to uncover possible Xnf7 homologs in humans, we identified TRIM39, which is 36% 
identical and 55% similar to Xnf7.   These proteins share a similar arrangement of N-
terminal RING and B-box domains and contain similar PRY and SPRY domains within 
their C-terminal regions, suggesting that TRIM39 might share functional properties with 
Xnf7 (Fig. 2.1A).  Using recombinant E1, E2 (UbcH5a, an E2 that could function with 
Xnf7), ubiquitin and TRIM39 as the only source of E3 activity, we found that TRIM39, 
like Xnf7, could autoubiquitylate.  Several E2s could support TRIM39 autoubiquitylation 
(including UbcH5a), while others (most notably UbcH10, an E2 used by the APC/C) 
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could not (Fig. 2.2A).  Moreover, RING-domain mutants expected to disrupt zinc 
binding (C44A and C52A) were deficient in enzymatic activity (Fig. 2.1B).  
To determine whether TRIM39 could inhibit the APC/C, we added either 
Maltose-Binding Protein (MBP) or MBP-TRIM39 protein to lysates prepared from HeLa 
cells that had been synchronized in nocodazole, and then released (by wash-out of the 
nocodazole).  As shown in Fig. 2.1C, Cyclin B1 was quickly degraded in the presence of 
recombinant MBP protein as these lysates exited from the mitotic arrest, while 
degradation of endogenous Cyclin B1 was nearly abolished by addition of recombinant 
MBP-TRIM39.  This inhibition was not observed using the C44A mutant, suggesting that 
E3 ubiquitin ligase activity is required for APC/C inhibition (Fig.2.1C). Indeed, Cyclin B1 
was more rapidly degraded in the presence of the catalytically-inactive TRIM39 mutant, 
suggesting that this protein might interfere with the functioning of the endogenous 
protein. To confirm a direct role for TRIM39 in APC/C inhibition, we incubated APC/C 
immunoprecipitated from HeLa cells with MBP or MBP-TRIM39, E1, E2, ubiquitin and 
radiolabeled in vitro translated Cyclin B1.   As shown in Fig. 2.1D, Cyclin B1 was well-
ubiquitylated by the isolated APC/C and this activity was markedly reduced by 
incubation with MBP-TRIM39, as predicted for a direct APC/C regulator. To exclude the 
possibility that TRIM39 inhibited the APC/C by titrating the available E2, we 
supplemented the in vitro ubiquitylation reaction with UbcH10, which supports APC/C, 
but not TRIM39, E3 ligase activity.   Under these conditions, TRIM39 still inhibited 
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ubiquitylation of Cyclin B1 by the APC/C (Fig. 2.1D).   We also showed that APC/C 
inhibition does not result simply from titrating any other limiting factor (e.g. ubiquitin) 
away from the APC/C by isolating TRIM39 truncation mutants that retained auto-
ubiquitylating activity (Fig. 2.2B), but lacked the ability to inhibit Cyclin B1 degradation 
(Fig. 2.2C).   Furthermore, TRIM39 had no effect on an unrelated E3 ubiquitin ligase, 
DIAP1, which still auto-ubiquitylated in response to binding of its regulator, Reaper, in 
MBP-TRIM39-supplemented cell lysates released from nocodazole arrest (Fig. 2.2D). 
Thus, TRIM39 does not generally suppress ubiquitylation/degradation of proteasomal 
substrates.  
2.4.2 TRIM39 inhibits MOAP-1 degradation during interphase 
Since TRIM39 had been reported to modulate the ubiquitylation and degradation 
of the MOAP-1 and we had now found that TRIM39 could inhibit the APC/C, we 
hypothesized that MOAP-1 might be an APC/C substrate. To see if temporal 
degradation of MOAP-1 in the cell cycle was consistent with a role for the APC/C, we 
prepared HeLa cell extracts arrested at either prometaphase by nocodazole or further 
released for 0, 1 or 4 h, (representing prometaphase, metaphase or G1 extracts, 
respectively) and supplemented these extracts with radiolabeled, in vitro translated 
MOAP-1.  MOAP-1 was not degraded in prometaphase or metaphase extracts, but was 
quickly degraded in G1 extracts, suggesting a role for Cdh1-activated APC/C in MOAP-
1 degradation (Fig. 2.3A). Indeed, endogenous MOAP-1 levels were reduced in cells 
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released into G1 phase from nocodazole arrest, slightly delayed relative to endogenous 
Cyclin B1 degradation (Fig. 2.3B). This cell cycle-regulated degradation was similar to 
that seen for other APC/C substrates.  
Since TRIM39 inhibited the APC/C (Fig. 2.1C and D), we asked whether this 
MOAP-1 degradation could be inhibited by TRIM39.  Therefore, we added radiolabeled 
MOAP-1 or geminin (a control APC/C substrate) into cell lysates prepared from 
nocodazole-arrested cells and then pre-incubated with MBP-TRIM39 WT or MBP-
TRIM39 C44A proteins during the release into G1 phase. Although MOAP-1 
degradation was not as robust as gemnin degradation, both proteins were degraded 
more rapidly in lysate containing MBP-TRIM39 C44A than in lysate containing MBP-
TRIM39 (Fig. 2.3C). These data are consistent with the idea that APC/C promotes 
degradation of MOAP-1 and that this degradation can be inhibited by TRIM39. 
2.4.3 MOAP-1 is an APC/CCdh1 substrate 
Since MOAP-1 was degraded in G1 cell lysates, we reasoned that the APC/CCdh1 
might ubiquitylate MOAP-1 to promote its proteasomal degradation. To assess this, we 
performed degradation assays using radiolabeled in vitro translated MOAP-1 as a 
substrate and found MOAP-1 degradation to be significantly slower in lysates in which 
Cdh1 had been knocked down using siRNA (Fig. 2.4A). Moreover, overexpression of 
HA-Cdh1 in conjunction with Myc-MOAP-1 in 293T cells led to a dose-dependent 
decrease in MOAP-1 levels, even in unsynchronized cells (Fig. 2.4B).  While TRIM39 
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knock-down led to loss of MOAP-1 protein, MOAP-1 levels were restored by coordinate 
knock-down of both TRIM39 and Cdh1 (Fig. 2.5A). Furthermore, TRIM39 WT, but not 
C44A protein substantially inhibited ubiquitylation of MOAP-1 by the APC/C in vitro 
(Fig. 2.5B).  Consistent with these findings, MOAP-1 and Cdh1 could co-
immunoprecipitate (Fig 2.4C and D).   
Our identification of TRIM39 as a candidate APC/C inhibitor was based on its 
sequence homology with Xnf7 (Casaletto et al., 2005).  To determine if Xnf7 and TRIM39 
were functionally similar, we knocked down TRIM39, resulting in nearly undetectable 
levels of MOAP-1; when WT, but not RING mutant Xnf7 was transfected into these cells, 
MOAP-1 was stabilized, suggesting that Xnf7 can, like TRIM39, inhibit APC/C-mediated 
MOAP-1 degradation (Fig. 2.5C). 
In scanning the MOAP-1 sequence, we identified four potential D-box sequences 
that might confer recognition by Cdh1 (Fig. 2.6A). As shown in Fig. 2.6A, we mutated 
the underlined D-box consensus amino acids to Ala and transfected MOAP-1 wild type 
or D-box mutant constructs into 293T cells. MOAP-1 WT protein could be co-
immunoprecipitated with HA-Cdh1 whereas MOAP-1 mutated at all four putative D-
boxes (MOAP-1 MT) could not (Fig. 2.6B; we saw slight reduction of binding with each 
single D-box mutant, data not shown).  Mutation of the D-box sequences caused a 
similar reduction in Cdh1/MOAP-1 interactions when recombinant His-Cdh1 was 
pulled down using MBP-MOAP-1 (WT or MT (Fig. 2.6C). Moreover, Myc-MOAP-1 MT 
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protein expressed in 293T cells was notably stabilized when compared with MOAP-1 
WT after cycloheximide treatment (Fig. 2.6D).  MOAP-1 WT was more robustly 
ubiquitylated than MOAP-1 MT both in cells overexpressing Cdh1 and treated with the 
proteasome inhibitor, MG132, and by the purified APC/CCdh1 in vitro (Fig 2.6E and F). 
These data strongly suggest that MOAP-1 degradation results from APC/CCdh1-mediated 
D-box dependent ubiquitylation.  
2.4.4 Depletion of Cdh1 enhances susceptibility to apoptosis in 
response to DNA damage  
MOAP-1 has been reported to enhance apoptosis by activating Bax and 
knockdown of TRIM39 has been reported to decrease etoposide-dependent apoptosis. 
We predicted that loss of Cdh1 would lead to elevation of MOAP-1 (as this would 
disable the APC/C in much the same way as TRIM39 expression) and enhancement of 
etoposide-induced Bax activation. In agreement with this, in 293T cells treated with 
etoposide, the 6a7 antibody that recognizes conformationally active Bax, 
immunoprecipitated greater amounts of Bax in cells knocked down for Cdh1 than in 
cells treated with control siRNA.   Cells treated with siRNA for MOAP-1 activated less 
Bax than control cells.   Importantly, the increased Bax activation seen following 
knockdown of Cdh1 was significantly dampened following MOAP-1 knockdown (Fig. 
2.7A; see Fig. 2.7B for protein levels following knockdown). 
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To evaluate the effect of Cdh1/MOAP-1 knockdown on chemotherapy-induced 
apoptosis, we treated PC3 prostate cancer cells with siRNA directed against Cdh1, 
MOAP-1 or both and monitored cell death by PI staining and flow cytometry. As shown 
in Fig. 2.7C and D, apoptosis was increased in Cdh1 knockdown cells in response to 
both etoposide and cisplatin treatment, but this increase was partially lost in cells that 
were ablated for both Cdh1 and MOAP-1 (see Fig. 2.7E for knockdown efficiency).   This 
effect was even more marked with cisplatin than etoposide and the observed changes in 
cell death in response to cisplatin correlated well with caspase 3 cleavage (Fig. 2.7F).  
Thus, while there are likely additional APC/CCdh1 substrates that contribute to the 
increased apoptotic response following loss of Cdh1, MOAP-1 degradation by APC/C 
contributes to setting the apoptotic threshold.  
2.5 Discussion 
2.5.1 TRIM39 as a novel inhibitor of APC/C    
    The data presented here identify TRIM39 as a new human E3 ligase able to 
regulate the APC/C and explain the previously reported link between TRIM39 and 
MOAP-1 abundance. Moreover, they demonstrate a role for the APC/CCdh1 in controlling 
apoptosis through degradation of the Bax activator MOAP-1. Currently, it is not clear 
how TRIM39 inhibits the APC/C. Like Xenopus Xnf7, the E3 ligase activity of TRIM39 is 
required for this inhibition (Casaletto et al., 2005). TRIM39 can co-immunoprecipitate 
with the core APC/C (unpublished observations) and it is possible that it can 
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ubiquitylate an APC/C subunit or an associated regulator. Alternatively, TRIM39 may 
require autoubiquitylation to act as an APC/C inhibitor. 
It would be of interest to determine whether TRIM39 functions at a particular cell 
cycle stage as other APC/C inhibitors have cell cycle-specific functions; for example, 
Emi1 inhibits APC/C during the G1 to S transition while Mad2 and BubR1 assume this 
role in prometaphase (Jackson, 2004; Skaar and Pagano, 2009). Our results indicate that 
TRIM39 can inhibit APC/C activity towards Cyclin B1, geminin, and MOAP-1, 
suggesting that TRIM39 can inhibit APC/C activity towards multiple substrates.  
Nonetheless, it remains possible that there is some substrate specificity to this inhibition. 
2.5.2 APC/C links to apoptosis  
Previous reports suggested that MOAP-1 was regulated at the level of protein 
stability.  Our results indicate that the APC/CCdh1 can ubiquitylate MOAP-1, providing a 
link between the APC/CCdh1 and regulation of apoptosis.  Indeed, MOAP-1 has been 
reported to be a short half-life protein (~25 mins) (Fu et al., 2007) and its stability is 
decreased once cells enter G1, the point where APC/CCdh1 is known to act (Fig. 2.3). It is 
not yet clear if MOAP-1 has apoptotic effects that are cell cycle-specific or how cell cycle-
specific degradation of MOAP-1 would help coordinate cell cycle status and apoptosis.  
Interestingly, etoposide treatment can stabilize MOAP-1 (Fu et al., 2007), suggesting that 
there are pathways linking the status of DNA or activation of DNA damage checkpoints 
to either TRIM39 or APC/CCdh1.   
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Recently, it was reported that APC/CCdc20 ubiquitylates the anti-apoptotic Bcl-2 
family protein Mcl-1 after a prolonged M phase arrest (Harley et al., 2010). In that 
MOAP-1 is stable during M phase and is not degraded until G1, it may participate in 
relaying the apoptotic signal after Mcl-1 is degraded in the event of prolonged M phase 
arrest. Under normal circumstances, at M phase exit, APC/CCdc20 is degraded by 
APC/CCdh1 followed by MOAP-1 degradation.  At the same time, Mcl-1 can reaccumulate 
to prevent cell death. Although there are clearly multiple inputs into the cellular 
decision to live/die, this hand-off of apoptotic control between various short half-life 
proteins throughout the cell cycle may allow maximum flexibility/rapid cellular changes 
in response to cell cycle cues or cellular damage  
    Recently, it was reported that siRNA-mediated knock-down of Cdh1 in 
primary cortical neurons leads to apoptotic cell death (Almeida A et al., 2005)   It has 
been hypothesized that the APC/C helps to maintain the differentiated state by 
preventing accumulation of Cyclin B1 and aberrant cell cycle re-entry. According to this 
scenario, death from loss of Cdh1 would follow a failure to suppress cell cycle 
progression (Aulia and Tang, 2006).  These effects may more directly stem from 
stabilization of apoptotic regulators that are APC/C substrates. As MOAP-1 belongs to 
the human PNMA family and this family of proteins is particularly highly expressed in  
the brain, it would be interesting to determine if MOAP-1 accumulation also contributes 
to apoptosis in neurons ablated for Cdh1 (Schuller et al., 2005). Similarly, it has been 
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suggested that Cdh1 degradation after UV irradiation may promote cell death due to 
aberrant accumulation of Cyclin B1 (Liu et al., 2008). Our results raise the interesting 
possibility that Cdh1 degradation following irradiation might also lead to increases in 
MOAP-1 abundance to sensitize cells to UV-induced apoptosis. 
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Figure 2. 1: TRIM39 is an Xnf7-related E3 ubiquitin ligase, and ligase activity is 
required for APC/C inhibition. 
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Figure 2.1:  (A) Schematic representation of the domains found within Xnf7 and TRIM39 
proteins. BBC represents the coiled-coil region C terminal to the B-Box domains. (B) In 
vitro ubiquitylation using recombinant TRIM39 WT, RING domain mutant, C44A, and 
C52A in the absence or presence of ubiquitin and E1/E2 (UbcH5a). (C) Cell lysates were 
prepared from HeLa cells synchronized after a 1-hrelease from nocodazole (allowing 
further release in vitro) and incubated with 1 μM recombinant proteins, as indicated. 
Samples were collected and immunoblotted with Cyclin B1 antibody. (D) Radiolabeled 
in vitro translated Cyclin B1 fragment (1–106) was incubated with ubiquitin, E1 and E2 
(UbcH5a, UbcH5c, or UbcH10, as indicated), ATP, His-Cdh1, and APC/C 
immunoprecipitated from HeLa cell G1 lysates using Cdc27 antibody. Reactions were 
supplemented with control buffer, MBP, MBP-TRIM39 WT, or C44A recombinant 
protein for 45 min. Samples were detected by SDS-PAGE and autoradiography. 
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Figure 2. 2: Specificity of TRIM39 
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Figure 2.2: (A) TRIM39 can function with several E2s but cannot function with UbcH10. 
MBP-TRIM39 WT or C44A recombinant proteins were incubated with 240 μM ubiquitin, 
12.5 nM E1, 10 μM ATP, and different E2 proteins in vitro for 1 h, an autoubiquitylation 
was detected by immunoblotting using anti-ubiquitin antibody. (B) 1 μM MBP, MBP-
TRIM39 WT, C44A, 1–105, and 1–336 fragments of TRIM39 were incubated with 240 μM 
ubiquitin, 12.5 nM E1 and 250 nM E2 (UbcH5a and UbcH5c), 10 μM ATP, and 
radiolabeled in vitro translated TRIM39 C44A protein for 30 min at 30°C, and samples 
were resolved by SDS-PAGE and autoradiography. (C) 1 μM MBP, MBP-TRIM39 WT, 
C44A, 1–105, 1–150, and 1–336 recombinant proteins were incubated in nocodazole 
synchronized cell lysates, and samples were taken at the times indicated. Samples were 
resolved by SDS-PAGE and detected by anti–Cyclin B1 and anti-actin immunoblotting. 
(D) 1 μM MBP and MBP-TRIM39 WT, 7.5 μM Reaper recombinant proteins, and 
radiolabeled in vitro translated DIAP1 were incubated in nocodazole-synchronized cell 
lysates, and samples were taken at the times time indicated. Samples were resolved by  
SDS-PAGE gel and detected by autoradiography or anti–Cyclin B1 immunoblotting. 
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Figure 2. 3: MOAP-1 protein is degraded in a cell cycle–specific manner, and 
TRIM39 attenuates the degradation. 
Figure 2.3: (A) HeLa cells were synchronized at prometaphase with nocodazole and 
collected at the indicated times after release. Radiolabeled in vitro translated Cyclin B1 
and MOAP-1 proteins were incubated in each lysate. Samples were taken at each time 
point, and reactions were stopped by addition of SDS loading buffer. (B) HeLa cells were 
synchronized with nocodazole and collected after release at the indicated times. Lysates 
were analyzed by immunoblotting with the indicated antibodies. (C) 1 μM MBP-TRIM39 
WT and C44A recombinant proteins were incubated in nocodazole-synchronized cell 
lysates for 3 h and then supplemented with in vitro translated, radiolabeled MOAP-1 or 
geminin. Samples were taken at each time point, and reactions were stopped by addition 
of SDS loading buffer. The line graphs below represent quantitation of three 
independent experiments. Error bars are SD. 
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Figure 2. 4: Cdh1 regulates MOAP-1 stability.  
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Figure 2.4: (A, top) HeLa cells were treated with control or Cdh1 siRNA, arrested in 
nocodazole, released for 4 h, and lysed, and lysates were supplemented with 
radiolabeled in vitro translated MOAP-1 protein. Samples were withdrawn into SDS 
loading buffer at the indicated times and resolved by SDS-PAGE and autoradiography. 
(bottom) Immunoblot of Cdh1 from the Cdh1 siRNA–treated (siCdh1) cells above. siCtr, 
siRNA control. (B) 293T cells were transfected with 0.5 μg Myc–MOAP-1 plasmid and 
increasing amounts of HA-Cdh1, as indicated. Cell lysates were collected and probed 
with anti-Myc, -HA, or -actin antibody. Relative Myc-MOAP-1 levels (normalized to 
levels seen in the absence of exogenous Cdh1 in lane 1) are quantitated below based on 
three repetitions of the experiment. Error bars are SD. (C) 293T cells were transfected 
with 0.5 μg HA-Cdh1 and 1.5 μg Myc–MOAP-1. Cell lysates were prepared and 
immunoprecipitated (IP) by normal IgG or anti-HA antibody and probed with anti-HA 
or -Myc antibody. (D) Anti-Cdh1 or control IgG immunoprecipitates from 20 μM 
MG132-treated 293T cells were immunoblotted with anti–MOAP-1 or anti-Cdh1 
antibody. 
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Figure 2. 5: Control of MOAP-1 ubiquitylation and degradation by TRIM39 
and Xnf7 
Figure 2.5: (A) 293T cells were transfected with control (siCtr), Cdh1 (siCdh1), or 
TRIM39 (siTRIM39)-targeted siRNA for 72 h. Cell lysates were immunoblotted with 
anti–MOAP-1, Cdh1, TRIM39, or actin antibodies. (B) 1 µM recombinant MBP, MBP-
TRIM39 WT, or C44A proteins were incubated separately with MBP–MOAP-1 protein, 
240 µM ubiquitin, 12.5 nM E1 and 250 nM E2 (UbcH5a, UbcH10, and Ube2S), 10 µM 
ATP, and APC/C immunoprecipitated with anti-Cdc27 antibody from HeLa G1 cell 
lysates. Samples were immunoblotted with anti–MOAP-1 antibody. (C) Control or 
TRIM39 knockdown 293T cells were transfected with control, Xnf7 WT, or Xnf7 
C160/163A for 48 h. Cell lysates were immunoblotted with anti–MOAP-1, TRIM39, Xnf7, 
or actin antibodies. 
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Figure 2. 6: MOAP-1 is an APC/CCdh1 substrate with D-box motifs.  
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Figure 2.6: (A) Sequences of putative D-boxes on MOAP-1. D-box consensus amino 
acids mutated to Ala and transfected MOAP-1 WT or D-box mutant constructs into 293T 
cells are underlined. (B) 293T cells were transfected with HA-Cdh1 and Myc–MOAP-1 
WT or MOAP-1 MT. Cells were collected and immunoprecipitated (IP) by anti-HA 
antibody. Samples resolved by SDS-PAGE were immunoblotted using anti-Myc or -HA 
antibodies. (C) MBP or MBP–MOAP-1 WT or MBP– MOAP-1 MT was incubated with 
His-Cdh1 for 2 h at 4°C, and proteins were retrieved from the mixture using amylose 
beads. After SDSPAGE, samples were immunoblotted with anti- MBP or -Cdh1 
antibodies. (D) 293T cells were transfected with Myc–MOAP-1 WT or Myc–MOAP-1 MT 
and treated with 100 µM cycloheximide (CHX). Cell lysates were prepared at the 
indicated times after cycloheximide treatment and immunoblotted with anti-Myc or -
actin antibodies. (E) 293T cells were transfected with Myc–MOAP-1 WT or MT in the 
presence or absence of HA-Cdh1. After 48 h, cells were treated with 20 µM MG132 for 16 
h, and lysates were collected for immunoblotting with anti-Myc, -HA, or -actin 
antibodies. (F) Recombinant MBP–MOAP-1 WT or MT proteins were incubated with 
ubiquitin, E1 and E2 (UbcH10 and Ube2S), ATP, and APC/C precipitated from HeLa G1 
cell lysates using anti-Cdc27 antibody. Samples were immunoblotted with anti–MOAP-1 
antibody. 
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Figure 2. 7: Higher Bax activation in Cdh1 knockdown cells as a result of 
MOAP-1. 
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Figure 2.7: (A) 293T cells treated with Cdh1 (siCdh1), MOAP-1 (siMOAP-1), or control 
siRNA (siCtr) were treated with control or 100 μM etoposide for 48 h. Bax activation was 
monitored by IP with 6a7 antibody from 293T cells followed by immunoblotting of total 
Bax (N20). Input lysates were immunoblotted with anti-actin and -Bax (N20) antibodies. 
(B) Cell lysates from A were immunoblotted with anti-Cdh1 or anti–MOAP-1 antibodies. 
(C) Control, Cdh1, and MOAP-1 knockdown PC3 cells were treated with 100 μM 
etoposide for 48 h. The percentage of cells with sub-G1 DNA content was measured by 
PI staining and flow cytometry. (D) PC3 cells were processed as in C but treated with 20 
μM cisplatin. (C and D) The asterisks indicate that the difference between the two 
experiments is significant (P < 0.05), using an unpaired t test. The data shown represent 
three independent experiments. Error bars are SEM. (E) Cdh1 or MOAP-1 was knocked 
down using siRNA in PC3 cells, and samples were immunoblotted for Cdh1, MOAP-1, 
or actin. (F) Cells treated as in D were lysed, and lysates were immunoblotted to detect 
caspase-3 processing.
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3. Ubiquitylation of p53 by the APC/C inhibitor TRIM39 
This chapter is adapted from (Zhang et al., 2012a) 
3.1 Summary 
As described in previous chapter, TRIM39 is a RINGdomain-containing E3 
ubiquitin ligase able to inhibit the anaphase-promoting complex (APC/C) directly. 
Through analysis of TRIM39 function in p53-positive and p53-negative cells, we have 
found, surprisingly, that p53-positive cells lacking TRIM39 could not traverse the G1/S 
transition. This effect did not result from disinhibition of the APC/C. Moreover, 
although TRIM39 loss inhibited etoposide-induced apoptosis in p53-negative cells, 
apoptosis was enhanced by TRIM39 knockdown in p53-positive cells. Furthermore, we 
show here that the TRIM39 can directly bind and ubiquitylate p53 in vitro and in vivo, 
leading to p53 degradation. Depletion of TRIM39 significantly increased p53 protein 
levels and cell growth retardation in multiple cell lines. We found that the relative 
importance of TRIM39 and the well-characterized p53-directed E3 ligas MDM2, varied 
between cell types. In cells that were relatively insensitive to the MDM2 inhibitor, 
nutlin-3a, apoptosis could be markedly enhanced by siRNA directed against TRIM39. As 
such, TRIM39 may serve as a potential therapeutic target in tumors with WT p53 when 
MDM2 inhibition is insufficient to elevate p53 levels. 
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3.2 Introduction 
E3 ubiquitin ligases are essential for cell cycle transitions, controlling the 
abundance of many key cell cycle regulators such as Cyclin proteins and their inhibitors 
(Wickliffe et al., 2009). In addition, E3 ligases such as MDM2, a ligase that targets the p53 
tumor suppressor, are known to control the cellular response to DNA damage including 
cell cycle arrest and the induction of apoptosis (Haupt et al., 1997; Honda et al., 1997; 
Kubbutat et al., 1997) 
Recently, we reported that involvement of the TRIM39 E3 ubiquitin ligase in 
controlling DNA damage-induced apoptosis through inhibition of the APC/C, a multi-
protein ubiquitin ligase that controls multiple cell cycle regulators including Cyclins, 
geminin, and others (Huang et al., 2012).  Surprisingly, analysis of cell cycle progression 
in cells lacking TRIM39 now suggests that it also might be important for G1/S 
progression/initiation of DNA replication in some cell types, but that a target other than 
the APC/C was likely involved.     
       p53 is a sequence-specific transcription factor that controls a host of genes 
important for cell death and proliferation (Vousden and Lane, 2007).   p53 protein is 
crucial for protecting cells in times of stress through a combination of cell cycle arrest, 
apoptosis, cellular senescence, DNA repair and autophagy  (Lane, 1992; Vogelstein et al., 
2000).    A variety of stressors can engage the p53 pathway, and p53 mutations, often 
lying within the p53 DNA-binding domain or within its protein interaction domains are 
 75 
present in greater than half of human cancer cases (Hainaut and Hollstein, 2000; Toledo 
and Wahl, 2006).      
     Given the centrality of p53 in the cellular stress response and the potential 
deleterious impact of alterations in p53 levels (eg. cell cycle arrest, cell death) under non-
stressed conditions, levels of cellular p53 are tightly controlled via ubiquitin-mediated 
proteasomal degradation (Brooks and Gu, 2011; Kruse and Gu, 2009). The most 
intensively-studied p53-directed E3 ligase is MDM2, proven in many settings to promote 
p53 proteasomal degradation (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 
1997).  Indeed, MDM2 inhibitors, such as nutlin-3a, are potential cancer therapeutics 
aimed at increasing p53 abundance to reduce proliferation and enhance tumor cell 
death/senescence (Shangary et al., 2008; Vassilev et al., 2004).   Despite the importance of 
MDM2 in regulating p53 levels, p53 is susceptible to degradation in MDM2-deficient 
mice (Ringshausen et al., 2006), indicating the presence of other E3 ligases able to target 
p53.  In this regard, several E3 ligases including Pirh2, COP1, ARF-BP1, CHIP, 
CARP1,CARP2 can promote p53 ubiquitylation and degradation under specific 
circumstances and/or in specific cell types (Brooks and Gu, 2011).  
Here we report that the TRIM39 E3 ubiquitin ligase, previously identified as a 
regulator of the APC/C, has a dual role as a direct E3 ubiquitin ligase for p53.   
Accordingly, the G1/S arrest observed following depletion of TRIM39 was dependent on 
p53.  The ability of TRIM39 to induce p53 ubiquitylation and degradation did not 
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depend on the APC/C and was also independent of MDM2. Accordingly, for several cell 
lines that were relatively insensitive to nutlin-3a, depletion of TRIM39 increased 
apoptotic cell death.  This identification of a previously unknown negative regulator of 
p53 suggests that there are likely to be as-yet-unexplored strategies for elevating p53 for 
therapeutic benefit. 
3.3 Materials and methods 
3.3.1 Cell culture and synchronization 
 Cultured cells were maintained in the indicated media supplemented with 10% 
FBS: ARPE-19, human telomerase reverse transcriptase-immortalized retinal pigment 
epithelial cell line (hTERT-RPE), MCF-7, A549, H1299, U-87MG, T98G, JEG-3 (DMEM), 
22Rv1, PC3 (RPMI 1640), U-2OS, and HCT116 (McCoy’s 5A). Stable knockdown of p53 
in hTERT-RPE was performed using the vector shp53-pLKO.1-puro (plasmid 19119; 
Addgene) (Godar et al., 2008). For nocodazole synchronization, cells were double 
thymidineblocked using 2.5 mM thymidine and released into medium containing 100 
ng/mL nocodazole. To arrest cells at G1 phase by serum starvation, hTERT-RPE cells 
were maintained in serumfree media for 6 d before adding back normal media to 
commence the time course. 
3.3.2 siRNA knockdown  
Lipofectamine RNAiMax (Invitrogen) was used for siRNA transfections. The 
following siRNAs were used: tripartite motif 39 (TRIM39) siRNA (J-007028-07: 
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GCAACUAGGCAGUAUGGUG, J-007028-08: GAAGAAUGCUGCACCACUU, and 
SMARTpool L-007028-00; Dharmacon), APC11 siRNA (L006992- 00-0005; Dharmacon), 
p53 siRNA (TP53HSS186391; Invitrogen), murine double minute 2 (MDM2) siRNA 
(UUCCGAAGCUGGAAUCUGUGAGGUG), and control siRNA directed against firefly 
luciferase (CGUACGCGGAAUACUUCGA). 
3.3.3 Plasmids and cell transfection 
 pcDNA3-TRIM39 and pMAL-c2x-TRIM39 were as previously described (Huang 
et al., 2012). pEGFP-C1 vector was from Clontech. Cells were transfected with X-
tremeGENE 9 (Roche) per the manufacturer’s instructions. 
3.3.4 Antibodies, western blotting, and immunoprecipitation  
The following antibodies were used: anti-actin (sc-1616-R), anti-Cyclin B1 (sc-
245), anti-geminin (sc-13015), anti-Cyclin A (sc-751), antip53 (sc-126), anti-MDM2 (sc-
965), anti-IκB-α (sc-371), anti-HA (sc-7392), anti-Myc (sc-40), anti-GFP (sc-9996), and 
anti-GST (sc-138) (all from Santa Cruz Biotechnology); anti-lamin B (ab16048) and anti-
maltose binding  protein (anti-MBP, ab9084) (both from Abcam); anti-p21 (556431; BD 
Pharmingen); and anti-Emi1 (37-6600; Invitrogen). For secondary antibodies, antimouse 
or anti-rabbit light chain-specific HRP antibodies (Jackson ImmunoResearch 
Laboratories) were used for Western blotting of coimmunoprecipitation. For TRIM39 
endogenous coimmunoprecipitation, cells were cross-linked with DSP 
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(Dithiobis[succinimidyl propionate]) (22585; Thermo Scientific) as described (Zlatic et 
al., 2010). 
3.3.5 Quantitative real-Time PCR analysis 
Quantitative real-time PCR analysis was carried out as described (Zhang et al., 
2011). All samples were amplified in triplicate, and every experiment was repeated at 
least two times. Relative gene expression was converted using the 2−ΔΔCt method 
against the internal control GAPDH housekeeping gene. The following primers were 
used: APC11 (forward: CAG GAT GGC ATT TAA CGG ATG, reverse: AGA CTC TTC 
CCT AGA CAT CAG G), Bax (forward: AGT GTC TCA AGC GCA TCG, reverse: AAG 
TCC AAT GTC CAG CCC), Cyclin A (forward: CCAAGAGGACCA GGA GAA TAT C, 
reverse: CGC AGG CTG TTT ACT GTT TG), Cyclin B1 (forward: CTT TCG CCT GAG 
CCT ATT TTG, reverse: GTA TTT TGG TCT GAC TGC TTG C), Cyclin D1(forward: 
CAT CTA CAC CGA CAA CTC CAT C, reverse: GTT CAA TGA AAT CGT GCG G.), 
Cyclin E (forward: GAT CTC TGT GTC CTG GAT GTT G, reverse: GTC TCT GTG GGT 
CTG TAT GTT G), Emi1 (forward: GTG TCT AAA GTG AGC ACA ACT TG, reverse: 
TTC TCT GGT TGA AGC ATG AGG), GAPDH (forward: ACA TCG CTC AGA CAC 
CAT G, reverse: ATG ACA AGC TTC CCG TTC TC), geminin (forward: TCC CAG 
TATGAA GCA GAA ACA AG, reverse: CAG GGCTGG AAG TTG TAG ATG), MDM2 
(forward: AAG GAG AGC AAT TAG TGA GAC AG, reverse: TTA CAC CAG CAT 
CAA GAT CCG), p16 (forward: CAC CAG AGG CAG TAA CCATG, reverse: TGA TCT 
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AAG TTT CCC GAG GTT TC), p21 (forward: TGT CAC TGT CTT GTA CCC TTG, 
reverse: ACA CAA ACT GAG ACT AAG GCA G), p27 (forward: TCT GAG GAC ACG 
CAT TTG G, reverse: AAT TCG AGC TGT TTA CGT TTG AC), p53 (forward: TGC GTG 
TGG AGT ATT TGG ATG, reverse: AGG ACA GGC ACA AAC ACG), and 
retinoblastoma-associated protein (pRB) (forward: ACC AAT ACC TCACAT TCC TCG, 
reverse: GGT CGC TGT TAC ATA CCA TCT). 
3.3.6 Cytosol and nuclei fractionation 
Cytoplasmic and nuclear extracts were isolated by using the NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Thermo Scientific) following the manufacturer’s 
instructions. 
3.3.7 Immunofluorescence and live cell imaging 
Cells were cultured on glass coverslips in six-well plates. Cells were fixed with 
4% (wt/vol) paraformaldehyde (PFA) prepared in PBS for 15 min and then 
permeabilized with PBS containing 0.5% (vol/vol) Triton X-100 for 5 min. Fixed cells 
were incubated with the appropriate primary antibodies in 5% nonfat dry milk, 
followed by incubation with the appropriate Alexa Fluor 488-conjugated secondary 
antibodies (Invitrogen) for 1 h and Hoechst 33258 (Molecular Probes) for 5 min to stain 
the nuclei. Fluorescent images were acquired using a Leica SP5 confocal scanning 
microscope. Images were analyzed using MetaMorph software (MDS Analytical 
Technologies). Timelapse phase-contrast images were collected every 10 min from cells 
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grown in glass-bottomed plates (MatTek) using a Zeiss Axio Observer Z1 microscope 
with a Photometrics Coolsnap ES2 camera. 
3.3.8 In vitro ubiquitylation 
Briefly, immunoprecipitated HA-p53 from 293T cells or 0.5 µg of GST-p53 (14-
865; Millipore) was incubated with 1 µg of MBP-TRIM39 (1 h at 30 °C) with 50 ng of 
rabbit E1, 1 µg of UbcH5a, 10 µg of ubiquitin, and 3 mM ATP brought to 40 µL with 
buffer [25 mM Hepes (pH 7.5), 10 mM NaCl, 3 mM MgCl2, 10 mM DTT, and 0.05% 
Triton X-100]. Reactions were stopped by adding SDS sample buffer, resolved by 
SDS/PAGE, and analyzed by immunoblotting. 
3.3.9 In vivo ubiquitylation 
HEK293 cells were transiently transfected with TRIM39, myc-p53, HA-ubiquitin, 
or GFP constructs as indicated. After 36 h, the transfected cells were treated with 20 µM 
MG132 for a further 8 h. Cell lysates were prepared in radioimmunoprecipitation assay 
lysis buffer with protease inhibitor mixture and MG132 (20 µM). Myc-p53 was 
immunoprecipitated from the cell extract using anti-Myc antibodies, and Western 
blotting was performed to detect p53 ubiquitylation. 
3.3.10 Pull-down assays 
Pull-down assays were performed as previously described (Huang et al., 2012). 
Briefly, 2 µg of MBP or MBP-TRIM39 was incubated with in vitro-translated HA-p53 or 
2 µg of GST-p53 for 2.5 h at 4 °C. Amylose beads were added for another 30 min to pull 
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down MBP proteins and washed five times with immunoprecipitation buffer. Samples 
were analyzed by immunoblotting. 
3.3.11 Growth curve and colony formation assay 
For growth curve assays, hTERT-RPE cells were transfected with the indicated 
siRNAs; 48 h later, 1 × 105 cells were reseeded to six-well plates, and cell numbers were 
counted every day. For colony formation assay, 500 cells were seeded to 6-cm or 10-cm 
cell culture dishes 48 h after siRNA transfection. After 12 d, cells were fixed with 4% 
PFA for 5 min, followed by staining with 0.05% Crystal Violet for 30 min and washing 
two times with tap water. The dishes were scanned to count colonies. 
3.3.12 Statistical analysis 
All results are expressed as the mean ± SD. Comparisons between two groups 
were made by an unpaired Student t test. A p value less than 0.05 was considered as 
statistically significant. All experiments were repeated at least three times to allow for 
appropriate statistical analyses. 
3.3.13 Flow cytometry analysis 
For the proliferation assay, the Click-iT EdU Alexa Fluor 488 Flow Cytometry 
Assay Kit (Invitrogen) was used to measure cell proliferation following the 
manufacturer’s instructions. For cell cycle analysis, cells were fixed in 70% ethanol 
(vol/vol) (prechilled at −20 °C) for at least 30 min and incubated in 15 µg/mL RNase A 
(Roche) for 15 min, followed by incubation in 50 µg/mL PI (Sigma) for 30 min. For the 
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annexin V/PI apoptosis assay, cells (∼1 × 105) were collected and washed once with PBS, 
followed by incubation in annexin V (A13201; Invitrogen) solution [2.5 µL of annexinV 
in 50 µL of annexin V binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2)] for 
15 min and 300 µL of 2 µg/mL PI in annexin V binding buffer. Flow cytometry analysis 
was carried out with the use of a Becton–Dickinson FACScan apparatus and CellQuest 
software. 
3.4 Results 
3.4.1 Knockdown of TRIM39 induces G1/S arrest and inhibition of 
proliferation 
Based on its ability to inhibit the APC/C, we had postulated that TRIM39 protein 
might be a component of the spindle assembly checkpoint that prevents APC/C 
activation when chromosomes are not properly aligned on the mitotic spindle.  To assess 
this, we transfected cells with TRIM39-directed siRNA able to deplete greater than 90% 
of TRIM39 from hTERT-RPE cells (where we had seen a marked effect on APC/C-
mediated protein degradation), synchronized these cells using double thymidine block, 
release into nocodazole to disrupt the spindle and monitored cells by time-lapse 
microscopy or analyzed their DNA content by flow cytometry (Fig. 3.1A and 3.1B). We 
were surprised to find that the great majority of cells lacking TRIM39 (93%) never 
entered mitosis (Fig. 3.1A and 3.1B).  These data suggested that there might be another 
critical role for TRIM39 in promoting cell cycle progression.  Indeed, proliferation of the 
RPE cells was markedly dampened by loss of TRIM39, as shown by both cell growth 
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curves and colony forming assays (Fig. 3.2A and 2 B).   Moreover, EdU incorporation 
was significantly decreased after knockdown of TRIM39 (1.3% vs. control 25.9%, p<0.05), 
demonstrating that the lack of TRIM39 prevented DNA replication (Fig. 3.2C and 3.1C).   
Together, these data suggested that TRIM39 has a role at the G1/S transition (under 
normal, non-stressed conditions), in addition to its role in controlling apoptosis in 
response to DNA damage.  Indeed, cell death did not contribute to failure of TRIM39-
deficient cells to proliferate as depletion of TRIM39 had little effect on basal rates of cell 
death in hTERT-RPE cells as determined by Annexin V/PI staining (Fig. 3.1D).  
3.4.2 G1 arrest induced by depletion of TRIM39 is dependent on p53  
The APC/C inhibitor Emi1 enables DNA synthesis by allowing accumulation of 
APC/C substrates such as Cyclin A and other factors required for the G1/S transition 
(Machida and Dutta, 2007; Miller et al., 2006; Reimann et al., 2001a; Reimann et al., 
2001b). Thus, it remained possible that TRIM39 also controlled G1/S through its ability 
to modulate the APC/C.  hTERT-RPE cells were serum starved to arrest at G0/G1 phase,  
then released into serum-containing medium.  As shown in Fig. 3.3A, the levels of the 
APC/C substrates geminin and Cyclin A rapidly increased in a time dependent manner 
in control cells, whereas these increases were not observed in cells treated with TRIM39 
siRNA.   A similar decrease in Cyclin A and geminin accumulation could be seen upon 
loss of Emi1 (Fig. 3.3B).  However, additional analysis revealed a fundamental difference 
between loss of Emi1 and TRIM39; proteasome inhibition by MG132 was able to restore 
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Cyclin A and geminin levels following knockdown of Emi1, while proteasome inhibition 
had a minimal effect on the levels of these proteins following TRIM39 knockdown (Fig. 
3.3B).   These data suggested that the effect of TRIM39 on Cyclin A and geminin 
expression was unlikely to be a result of TRIM39-mediated APC/C inhibition.  
     To address these issues further, we performed quantitative real-time PCR on 
control cells or cells treated with TRIM39 siRNA.  As shown in Fig. 3.3C, there was a 
significant decrease in the levels of Cyclin A, geminin, and Emi1 mRNAs in the absence 
of TRIM39 (Fig. 3.3C). However, we observed a marked increase in the expression of 
mRNAs encoding p21 (but not p27 and p16), MDM2 and Bax after TRIM39 depletion.   
These genes are well known targets of the tumor suppressor p53, raising the possibility 
that p53 was, in some way, involved in the G1/S transition defect observed in cells 
lacking TRIM39. Therefore, we examined the effects of co-depletion of p53 and TRIM39. 
While the protein levels of p53 and p21 were increased coordinately with decreased 
Cyclin A and geminin proteins after depletion of TRIM39, control levels of these 
proteins was restored after co-depletion of TRIM39 and p53 (Fig. 3.3D). These data 
strongly suggested that the G1/S arrest resulting from TRIM39 depletion in RPE cells 
was exerted through p53.  Indeed, knockdown of p53 largely (albeit not completely) 
restored EdU incorporation and DNA replication following knockdown of TRIM39 (Fig 
3.3E, 3.4A, 3.4B and 3.4C).    Extending these results to other cell types, and consistent 
with this idea, we found that depletion of TRIM39 decreased EdU incorporation in cells 
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with wild type p53 (A549, U-87 MG, 22Rv1, MCF7, HepG2, HCT116 P53+/+), but had 
either a minor or no effect on EdU incorporation in p53 mutant or null cells (H1299, 
T98G, PC3, HCT116 P53-/-) (Fig. 3F).  Collectively, these data suggest that TRIM39 
depletion can induce accumulation of p53 and its target, p21, resulting in a failure to 
traverse the G1/S transition. 
3.4.3 TRIM39 interacts with p53 and regulates its stability 
Given the effects of TRIM39 on p53 levels, we tested whether TRIM39 and p53 
could interact.  As shown in Fig. 3.5A, TRIM39 and p53 proteins were both 
predominantly nuclear and the nuclear fraction of p53 was dramatically increased in 
abundance following TRIM39 depletion (Fig. 3.5A, also shown in micrographs in Fig. 
3.4D). In addition, we were able to co-immunoprecipitate p53 and TRIM39 with antisera 
directed against either protein (Fig. 3.5B, C, D, 3.6A, 3.6B).  Moreover, we were able to 
demonstrate a direct interaction between recombinant TRIM39 and p53 proteins in vitro 
(Fig. 3.6C, 3.6D).   
     Since TRIM39 depletion increased p53 protein levels and we had previously 
characterized TRIM39 as an RING E3 ligase, we monitored the effect of TRIM39 on p53 
protein stability and found, after depletion of TRIM39, that the half life of p53 was 
significantly increased (Fig. 3.7A, 3.8A, 3.8B).   Importantly, although protein levels of 
p21 were also dramatically increased after depletion of TRIM39, the p21 half life was not 
changed, indicating that TRIM39 does not regulate protein levels of p21 directly (Fig. 
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3.7A, 3.8A, 3.8B.)   Rather, it is likely that changes in p21 levels reflect changes in its 
transcriptional activator, p53. TRIM39 overexpression decreased levels of p53; this 
decrease was dependent on TRIM39 E3 ligase activity as overexpression of ligase-
deficient RING domain mutants could not promote p53 degradation, despite their 
ability to bind p53 (Fig 3.7B and 3.5D).  The proteasome inhibitor MG132 allowed 
preservation of p53 protein in the face of wild-type TRIM39 overexpression, consistent 
with a role for TRIM39 in p53 degradation (Fig. 3.9A). In addition, the half life of 
exogenously expressed p53 was significantly decreased upon coexpression of wild type 
TRIM39 and was actually increased with coexpression of the ligase-deficient RING 
domain mutant, likely acting in a dominant negative fashion to impede endogenous 
Trim 39 (Fig. 3.8C). 
Furthermore, ectopic expression of wild type TRIM39, but not the RING mutant 
protein, increased p53 ubiquitylation, consistent with the possibility that TRIM39 acts as 
a p53-directed E3 ubiquitin ligase (Fig. 3.9B).   In support of this idea, TRIM39 was able 
to directly ubiquitylate p53 in vitro (Fig. 3.7C, 3.9C). Given that we had previously 
reported that TRIM39 could regulate APC/C activity, we speculated that there might be 
an unknown connection between the APC/C and p53 stability.   However, depletion of 
Cdh1, the activator of APC/C in interphase, or APC11, a core subunit of the APC/C, had 
no effect on the ability of TRIM39 loss to elevate p53 levels (Fig. 3.11A, B), strongly 
suggesting that TRIM39 did not affect p53 levels by modulating the APC/C.    
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3.4.4 TRIM39 can synergize with MDM2 to affect cell growth and 
apoptosis 
There are a number of E3 ubiquitin ligases that have been reported to act on p53, 
most prominently MDM2 (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997).  
We wished to determine whether the regulation of p53 stability by TRIM39 was 
dependent upon MDM2 and thus we transfected H1299 cells lacking p53 with control or 
MDM2 siRNA, and examined the effects of TRIM39 on the stability of co-transfected 
p53.  As shown in Fig. 3.10A, TRIM39 expression was able to induce p53 degradation 
even in the absence of MDM2. We also did not observe any direct effects of TRIM39 on 
MDM2 (or vice versa).   Although TRIM39 knock-down was able to elevate MDM2 
levels (Fig. 3.12A), this was an indirect effect resulting from stabilization of p53 (and 
therefore, enhanced MDM2 transcription) because knock-down of TRIM39 in H1299 
cells lacking p53 had no effect on MDM2 levels (Fig. 3.12B). Moreover, it appears that 
TRIM39 and MDM2 bind to different domains of p53 as p53 mutants 
(L14Q/F19S,L22Q/W23S) that were unable to bind MDM2 bound as well to TRIM39 as 
the wild type p53 (Fig. 3.13A) (Lin et al., 1994). 
To assess the relative contributions of TRIM39 and MDM2 in controlling cell 
cycle progression across a range of p53 wild  type cell types, we knocked down TRIM39, 
MDM2, or both and measured EdU incorporation as well as protein levels of p53 and 
p21.   As shown in Fig 3.10B and 3.12A, MDM2 and TRIM39 knockdown had variable 
impact on cell cycle progression in a variety of different cell types, with both ligases 
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contributing to the overall p53 and p21 levels as well as the ability to undergo DNA 
replication.   That said, in cells where another p53-directed negative regulator (eg. 
MDMX in JEG-3 cells) is known to play a dominant role, neither knock-down of TRIM39 
nor MDM2 (or both) had a significant impact on EdU incorporation (Fig. 3.13B). 
    MDM2 has been considered a promising target for cancer chemotherapy in 
that elevating levels of p53 in p53-positive tumors has the potential to induce cell cycle 
arrest and/or apoptosis.   A number of MDM2 inhibitors have been developed, the most 
well known of which is nutlin-3a, a compound that interferes with the binding of p53 to 
MDM2 (Shangary et al., 2008; Vassilev et al., 2004).  In contrast, we found that nutlin-3a 
was unable to disrupt the interaction of TRIM39 with p53 (Fig. 3.13C; compare lanes 2 
and 5).   Given the variable relative importance of MDM2 in different cell types, these 
data suggest that nutlin-3a might have only partial effects in cells expressing both 
MDM2 and TRIM39.   Therefore, the utility of nutlin-3a as a therapeutic agent is likely to 
be restricted by the population of E3 ligases other than MDM2 (in this case, TRIM39) 
which contribute to p53 stability in a given cell type, particularly if those ligases, like 
TRIM39, are refractory to inhibition by nutlin-3a.   Given this, we hypothesized that co-
inhibition of TRIM39 would increase the efficacy of nutlin-3a in killing p53-positive 
cells.   Consistent with this idea, knock down of TRIM39 enhanced cell killing by nutlin-
3a in p53 wild type cells expressing both ligases, even in cells that were relatively 
refractory to nutlin-3a, such as MCF-7 breast cancer cells and A549 lung cancer cells  
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(Fig. 3.10C and D).  Importantly, nutlin-3a, either alone, or in combination with TRIM39 
knockdown, did not kill cancer cells in the absence of p53 (Fig. 3.10 D) (H1299, p53 null 
cancer cell).  
    We and others have reported that TRIM39 helps to induce apoptosis following 
DNA damage, due to its ability to elevate levels of the Bax activator MOAP-1 (by 
inhibiting MOAP-1 degradation by the APC/C).   However, based on the data shown 
here, it seems that TRIM39 can also be considered anti-apoptotic, as its loss can promote 
stabilization of p53 and cell death.  To further evaluate this issue, we knocked down 
TRIM39 in p53 wild type cell (A549) or p53 null cell (H1299) and treated with etoposide.   
As shown in Fig. 3.13D, knockdown of TRIM39 in the presence of functional p53 
enhanced etoposide-induced cell death.   In contrast, depletion of TRIM39 in cells 
lacking p53, dampened etoposide-induced apoptosis, likely at least in part, due to the 
effects of TRIM39 on the APC/C and its substrate, MOAP-1, as discussed further below.    
3.5 Discussion 
3.5.1 TRIM39 as a novel E3 ligase of p53 
p53 is a central regulator of cell death, proliferation, and senescence and enables 
the cell to withstand a wide variety of stressors (Brown et al., 2009; Kruse and Gu, 2009; 
Wickliffe et al., 2009).   For this reason, p53 mutation or deficiency contributes to a 
significant fraction of human tumors.  Although p53 functions are required in the face of 
cellular stress or damage, normal proliferation of the unperturbed cell requires that 
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intracellular levels of p53 be restrained.   Accordingly, a complex network of post-
translational modifications (acetylation, methylation, phosphorylation, etc) fine tunes 
p53’s half life, rendering it more or less susceptible to the action of E3 ubiquitin ligases 
(Kruse and Gu, 2009; Toledo and Wahl, 2006). 
Although the E3 ubiquitin ligase MDM2 is thought to be the primary 
determinant of p53 ubiquitylation and stability in a variety of cell types, it is clearly not 
the only relevant p53-directed ligase (Camus et al., 2003; Ringshausen et al., 2006).   
Aside from the observation that p53 can be degraded in MDM2-deficient mice, mutation 
of the known MDM2-targeted lysines on p53 does not prevent p53 ubiquitylation and 
degradation in cells (Camus et al., 2003).  Moreover, several other E3 ligases, including 
another TRIM family member, TRIM24, are capable of promoting p53 degradation 
(Allton et al., 2009). An additional level of complexity stems from the ability of several of 
the p53-directed ligases to control each other’s stability, potentially through direct 
interaction (Wang et al., 2011). 
 In this study, we identified TRIM39 as a novel E3 ligase directly regulating p53 
stability, and compared the differential effects of TRIM39 and MDM2 knock-down on 
cell proliferation, p53 stability and p21 induction in multiple cell lines. Interestingly, we 
found that the effect of these ligases varied in different cell types. For example, it seems 
that TRIM39 contributes more significantly than MDM2 to cell growth and p53 stability 
in hTERT-RPE cells. This may be of potential significance for diseases of the retina, for 
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example, macular degeneration, where p53 is important for controlling cell death in 
response to oxidative stress (Vuong et al., 2012). 
3.5.2 TRIM39 inhibition could be used for cancer treatment   
For tumors with wild type p53, numerous pharmacological approaches have 
been taken to up-regulate or stabilize p53 protein (Lane et al., 2010; Vassilev, 2007).  
Small molecules such as nutlin-3a and MI-219 are able to disrupt MDM2-p53 
interactions, thereby preventing MDM2-mediated p53 ubiqutiylation (Shangary et al., 
2008; Vassilev, 2007; Vassilev et al., 2004). While this approach to induce p53-mediated 
cell cycle arrest/apoptosis has been successful in many cancer cell lines and xenograft 
models (and is under investigation for treating human cancers), significant expression of 
other E3 ligases, such as TRIM39 would be expected to diminish the effects of nutlin-3a 
and similar molecules, unless the interaction of p53 with these other ligases was also 
disrupted. For example, nutlin-3a is already known to be ineffective in cells that express 
high levels of MDMX, another known p53-directed ligase (Hu et al., 2006; Patton et al., 
2006; Wade et al., 2006).   Given this, effective elevation of p53 in tumors may well 
require a cocktail of E3 ligase inhibitors tailored to the population of p53-directed ligases 
present in an individual tumor. Indeed, novel inhibitors that target both MDM2 and 
MDMX can impede growth and induce apoptosis in cells with high levels of both 
MDM2 and MDMX (Bernal et al., 2010; Lane et al., 2010; Reed et al., 2010).  
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In this study, we found that combining nutlin-3a with knockdown of TRIM39 
was effective in triggering apoptosis in cells that were otherwise nutlin-3a insensitive 
(eg. MCF7 and A549.)  However, this combination was not effective in JEG-3 cells, 
consistent with previous reports documenting high levels of MDMX expression in these 
cells. 
Many of the E3 ligases that target p53 are also transcriptional targets of p53 
(Brooks and Gu, 2011). Thus, while E3 ligase inhibition may elevate p53, p53 in turn can 
promote transcriptional up-regulation of the ligases, potentially overcoming the effect of 
the inhibitors. TRIM39 does not appear to be regulated by p53, as depletion of MDM2 
significantly increases the levels of p53 without affecting the levels of TRIM39. This 
might make TRIM39 a promising therapeutic target, but we would note that depletion of 
TRIM39 significantly increases protein levels of both p53 and MDM2; induced MDM2 
inhibition might therefore counter the effects of TRIM39 inhibition.  These observations 
again support the notion of an inhibitor cocktail as perhaps the most effective approach 
to elevating p53 levels. 
3.5.3 p53 status determines the outcome of TRIM39 activity     
      The identification of TRIM39 as a p53-directed ligase raises the question of 
how this activity may be related to its previously-described role as an APC/C inhibitor.  
It does not appear that the effects of TRIM39 on p53 are exerted through the APC/C nor 
do effects on the APC/C require p53 (as TRIM39 can inhibit the APC/C in p53-null cells).    
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Although TRIM39 E3 ligase activity is required to inhibit the APC/C, and TRIM39 can 
inhibit the purified APC/C in vitro, the direct target of TRIM39 in the APC/C has not yet 
been identified. It is possible that identification of determinants of p53 
recognition/binding by TRIM39 may shed light on the direct interactors of TRIM39 
within the APC/C. DNA damage-induced activation of Trim 39 appears to have 
different consequences depending on the p53 status of the cell. In the absence of p53, the 
Trim 39-mediated inhibition of the APC/C results in stabilization of MOAP-1, promoting 
Bax activation and apoptosis.  Additionally, while the ability of TRIM39 to inhibit the 
APC/C seems to be activated by DNA damage, TRIM39 knockdown can affect p53 levels 
even in the unperturbed cell cycle. Taken together, these data place TRIM39 as a 
regulator of several key processes in the proliferative cycle. Additional experiments will 
determine whether these functions are entirely independent and whether they can be 
manipulated to therapeutic advantage in the setting of cancer, eye disease, or other 
pathologies involving mis-regulation of p53. 
 94 
 
Figure 3. 1: Depletion of TRIM39 decreases cell proliferation. 
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Figure 3.1: (A) ARPE-19 cells were transfected with control or TRIM39 siRNA and 
released into nocodazole after a double thymidine block. Photomicrographs were taken 
every 10 min by time lapse for 24 h, and representative micrographs were selected for 
time points at 2-h intervals. Luc, luciferase. (Magnification: 165×.) (B) hTERT-RPE cells 
were transfected with control or TRIM39 siRNA and released into nocodazole for 16 h 
after the double thymidine block. Cells were collected and analyzed by flow cytometry. 
*P < 0.05 vs. control. (C) hTERT-RPE cells were transfected with control (C) or different 
TRIM39 siRNAs; the effect on TRIM39 protein levels was detected by Western blotting, 
and cell proliferation was detected by EdU (5-ethynyl-2-deoxyuridine) incorporation. *P 
< 0.05 vs. control. (D) hTERT-RPE cells were transfected with control or TRIM39 siRNA, 
and apoptosis was detected by annexin V and propidium iodide (PI) staining followed 
by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 96 
 
Figure 3. 2: TRIM39 depletion induces cell growth retardation. 
Figure 3.2: A) hTERT-RPE cells were transfected with control or TRIM39 siRNA, and 1 × 
105 cells were seeded in six-well plates 2 d after siRNA transfection. Cells were counted 
each day for 4 d. Luc, luciferase (B) Colony assay. Two days after siRNA transfection, 
500 cells were seeded in 60-mm dishes and cultured for 12 d, and the number of colonies 
was counted. *P < 0.05 vs. control. (C) hTERT-RPE cells were transfected with control or 
TRIM39 siRNA, and DNA replication was monitored by EdU incorporation. *P < 0.05 vs. 
control. 
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Figure 3. 3: Cell growth inhibition induced by TRIM39 depletion is p53-dependent. 
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Figure 3.3: (A) hTERT-RPE cells were arrested at G1 phase by serum starvation, and 
cells were harvested at different time points after adding back media with 10% FBS. The 
protein levels were detected by Western blotting with the indicated antibodies. Luc, 
luciferase. (B) Cells were transfected with control, TRIM39, or Emi1 siRNA; 48 h later, 
cells were treated with MG132 for a further 8 h. Western blotting was carried out to 
detect the protein level with the indicated antibodies. (C) Real-time PCR was carried out 
to detect the gene expression in control or TRIM39 knockdown cells. *P < 0.01 vs. 
control. (D) Control-shRNA or p53-shRNA cells were transfected with control or 
TRIM39 siRNA, and the protein levels were detected by Western blotting with the 
indicated antibodies. (E) Control-shRNA (c-shRNA) or p53-shRNA cells were 
transfected with control or TRIM39 siRNA, and cell proliferation was measured by EdU 
incorporation. *P < 0.05 vs. control. (F) Panel of cell lines with different p53 background 
was transfected with control or TRIM39 siRNA, and cell proliferation was detected by 
EdU incorporation. *P < 0.05 vs. control. 
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Figure 3. 4: Inhibition of cell growth induced by Trim 39 depletion is mediated 
by regulation of p53 stability.  
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Figure 3.4: (A) Control-shRNA (c-shRNA) or p53-shRNA hTERTRPE cells were 
transfected with control or TRIM39 siRNA; 48 h later, cells were treated with nocodazole 
for 18 h. Cells were harvested, and cell cycle profiles were determined by flow 
cytometry. *P < 0.05 vs. control. Luc, luciferase. (B and C) hTERT-RPE cells were 
transfected with control, TRIM39, or p53 siRNA as indicated; cell proliferation was 
detected by EdU (5-ethynyl-2′-deoxyuridine) incorporation, and protein levels were 
measured by Western blotting (*P < 0.05 vs. control; **P < 0.05 vs. siTRIM39) (B), and cell 
cycle profiles were determined by flow cytometry (C). (D) hTERT-RPE cells were 
transfected with control or TRIM39 siRNA, and the protein levels of p53 were detected 
by immunostaining. (Scale bar, 20 µm.) *P < 0.05 vs. control. 
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Figure 3. 5: TRIM39 localizes to the nucleus and interacts with p53. 
Figure 3.5:  (A) hTERT-RPE cells were transfected with control or TRIM39 siRNA, and 
cytoplasmic (Cyto) and nuclear extracts (Nuclei) were fractionated and analyzed by 
Western blotting with the indicated antibodies. The asterisk indicates nonspecific signal. 
(B and C) hTERT-RPE cells were cross-linked with DSP (Dithiobis[succinimidyl 
propionate]), and immunoprecipitation was carried out to detect the interaction between 
TRIM39 and p53. The asterisk indicates nonspecific signal. (D) 293T cells were 
transfected with HA-p53, TRIM39 WT, C44A, or C52A, respectively, as indicated. HA-
p53 was immunoprecipitated with anti- HA antibody, and Western blotting was carried 
out to detect the interaction between TRIM39 and HA-p53. The asterisk indicates 
nonspecific signal. c, control; CE, cell extract; IP, immunoprecipitation; WCL, whole cell 
lysate. 
 102 
 
Figure 3. 6: TRIM39 interacts with p53 in vitro and in intact cells.  
Figure 3.6: (A) hTERT-RPE cells were transfected with control (c) or TRIM39 siRNA; 48 
h later, TRIM39 was immunoprecipitated with anti-TRIM39 antibody and detected by 
Western blotting. CE, cell extract; IP, immunoprecipitation. (B) MCF7 cells were cross-
linked with DSP (Dithiobis[succinimidyl propionate]), and immunoprecipitation was 
carried out to detect the interaction between TRIM39 and p53. (C and D) Two 
micrograms of MBP or MBP-TRIM39 was incubated with in vitro-translated p53 (C) or 2 
µg of GST or GST-p53 (D) for 2 h at 4 °C, and amylose beads were added for a further 30 
min. Beads were washed five times with immunoprecipitation lysis buffer, and protein 
was detected by Western blotting. 
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Figure 3. 7: TRIM39 negatively regulates p53 levels. 
Figure 3.7: (A) hTERT-RPE cells were transfected with control or TRIM39 siRNA, and 
cells were treated with cycloheximide for the time courses indicated. The protein levels 
of p53 and p21 were detected by Western blotting, quantified using Odyssey software, 
and plotted against time to determine protein half-lives. Luc, luciferase. (B) H1299 cells 
were transfected with 0.2 µg of HA-p53, 0.1 µg of pEGFP-C1, and different amounts of 
TRIM39 WT or RING mutant-encoding plasmids as indicated. Cells were harvested 48 h 
after transfection, and protein levels were detected by Western blotting with the 
indicated antibodies. (C) In vitro ubiquitylation of p53 by TRIM39. 293T cells were 
transfected with HA-p53, and HA-p53 was immunoprecipitated and mixed with myelin 
basic protein (MBP)-TRIM39 and E1/E2/ubiquitin as indicated for 1 h at 30 °C. Reactions 
were stopped by adding sample buffer, and Western blotting was carried out to detect 
the ubiquitylation of p53. 
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Figure 3. 8: TRIM39 negatively regulates the half-life of p53.  
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Figure 3.8: (A and B) hTERT-RPE cells were transfected with control or TRIM39 siRNA, 
and cells were treated with cycloheximide for the times indicated. The protein levels 
were detected by Western blotting. Luc, luciferase. (C) H1299 cells were transfected with 
0.2 µg HAp53, 0.1 µg pEGFP-C1, and 1.5 µg of TRIM39 WT or RING mutant-encoding 
plasmids as indicated. Forty-eight hours later, cells were treated with cycloheximide for 
the times indicated. The protein levels of HA-p53 were detected by Western blotting, 
quantified using LI-COR Biosciences Odyssey software, and plotted against time to 
determine protein half-lives. EV, empty vector.  
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Figure 3. 9: TRIM39 can ubiquitylate p53 and regulate its stability.  
Figure 3.9: (A) H1299 cells were transfected with HA-p53, pEGFP-C1, and TRIM39 WT 
or RING mutants, and MG132 was added for a further 8 h before harvesting the cells. 
Cells were harvested, and protein levels were detected by Western blotting. EV, empty 
vector. (B) In vivo ubiquitylation of p53 by TRIM39. 293T cells were transfected with 
HA-ubiquitin, myc-p53, pEGFP-C1, TRIM39 WT, or RING mutant as indicated. Cells 
were treated for a further 8 h with MG132 before harvesting. Cells were lysed, Myc-p53 
was subjected to immunoprecipitation (IP) with anti-Myc antibody, and Western 
blotting was carried out to detect the ubiquitylation of p53 by TRIM39. (C) In vitro 
ubiquitylation of p53 by TRIM39. GST-p53 was mixed with MBP or MBP-TRIM39 and 
E1/E2/ubiquitin as indicated for 1 h at 30 °C. Reactions were stopped by adding sample 
buffer, and Western blotting was carried out to detect the ubiquitylation of p53. 
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Figure 3. 10: Regulation of p53 stability by TRIM39 is independent of MDM2.  
Figure 3.10: (A) H1299 cells were transfected with control or MDM2 siRNA first, and 
cells were then transfected with HA-p53, TRIM39 WT or RING mutants, and pEGFP-C1 
as indicated 8 h after siRNA transfection. Cells were harvested 48 h later, and protein 
levels were detected by Western blotting with the indicated antibodies. Luc, luciferase; 
EV, empty vector. (B) hTERT-RPE, MCF7, A549, 22Rv1, or HepG2 cells were transfected 
with control, TRIM39, or MDM2 siRNA as indicated. Forty-eight hours later, cell 
proliferation was monitored by EdU incorporation. *P < 0.05 vs. control. (C) MCF7 cells 
were transfected with control, TRIM39, or p53 siRNA as indicated; 48 h later, cells were 
treated with nutlin-3a for a further 48 h. Cells were harvested and stained with annexin 
V and PI, and apoptosis was detected by flow cytometry. *P < 0.05 vs. control. (D) A549 
or H1299 cells were transfected with control or TRIM39 siRNA, and 48 h later, cells were 
treated with nutlin-3a for a further 48 h. Apoptosis (as indicated by the presence of a 
sub- G1 population) was detected by flow cytometry. *P < 0.05 vs. control. 
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Figure 3. 11: Anaphase promoting complex (APC/C) is not involved in the 
regulation of p53 by TRIM39.  
Figure 3.11: (A) hTERT-RPE cells were transfected with control, TRIM39, or CDH1 
siRNA, and cells were harvested 48 h later. Protein levels in cell lysates were monitored 
by Western blotting with the indicated antibodies. (B) hTERT-RPE cells were transfected 
with control, TRIM39, or APC11 siRNA. Cells were harvested 48 h later, and protein 
levels were monitored by Western blotting with the indicated antibodies. The 
knockdown efficiency of siAPC11 was detected by quantitative PCR. Luc, luciferase. 
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Figure 3. 12: TRIM39 and MDM2 act independently.  
Figure 3.12: (A) hTERT-RPE (RPE), MCF7, A549, 22Rv1, or HepG2 cells were transfected 
with control, TRIM39, or MDM2 siRNA as indicated. Forty-eight hours later, protein 
levels were detected by Western blotting. *, nonspecific signal. (B) H1299 cells were 
transfected with control, TRIM39, or MDM2 siRNA. Forty-eight hours later, cells were 
harvested and Western blotting was carried out to detect protein levels. Luc, luciferase. 
*, nonspecific signal. 
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Figure 3. 13: TRIM39 and MDM2 interact with p53 differently. 
Figure 3.13: (A) 293T cells were transfected with HA-p53 and TRIM39 or MDM2 as 
indicated. Forty-eight hours later, cells were harvested and immunoprecipitation (IP) 
was carried out to detect the interaction between HA-p53 and TRIM39 or MDM2. CE, 
cell extract. *, nonspecific signal. (B) JEG-3 cells were transfected with control, TRIM39, 
or MDM2 siRNA, as indicated. Forty-eight hours later, cell proliferation was detected by 
EdU (5-ethynyl-2′-deoxyuridine) incorporation. (C) MCF7 cells were treated with nutlin-
3a for 6 h, and endogenous p53 or MDM2 was immunoprecipitated from MCF7 cells. 
The interaction between TRIM39, p53, or MDM2 was detected by Western blotting. c, 
control. *, nonspecific signal. (D) A549 or H1299 cells were transfected with control or 
TRIM39 siRNA; 48 h later, cells were treated with 100 µM etoposide for a further 48 h. 
Apoptosis (sub-G1 population) was detected by flow cytometry. *P < 0.05 vs. control.
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4. Conclusion and perspectives 
The coordination of cell cycle regulation and apoptosis signaling is critical for 
maintaining tissue homeostasis and differentiation. These controls are essential for 
determining whether a cell survives or dies when facing DNA damage or cellular 
stressors. If cell cycle and apoptosis controls are aberrant, detrimental outcomes such as 
cancer can occur. From past research, we know that these two pathways are complicated 
and integrated; therefore understanding the connection between these two pathways 
will further our understanding of how cells fine tune the two pathways and react in 
response to stress.       
In the research described in this dissertation, we found that the TRIM39 protein 
regulates both the cell survival and cell death pathways via the APC/C and p53. We 
found that TRIM39, which is an E3 ubiquitin ligase, is a novel inhibitor of the APC/C, 
the master E3 ligase that marks critical cell cycle regulators for destruction. The 
identification of MOAP-1 as an APC/C substrate links APC/C function to apoptosis. 
Furthermore, the discovery that p53 can be ubiquitylated by TRIM39 demonstrates that 
the tumor suppressor or oncogenic role of TRIM39 must be cell context-dependent. 
Taken together, these findings suggest that inhibiting TRIM39 could potentially be a 
novel cancer treatment in particular cancer cell types.          
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4.1 TRIM39 is an inhibitor of APC/C 
In chapter 2, we provide data demonstrating that TRIM39 can restrain APC/C 
activity. The TRIM39 project originated from the knowledge that there existed 
significant sequence similarity between TRIM39 and Xnf7, a Xenopus E3 ubiquitin ligase 
inhibitor of the APC/C. Like Xnf7, TRIM39 is a RING domain containing E3 ligase that 
can auto-ubiquitylate itself in vitro. We found that TRIM39 can inhibit the degradation 
of the canonical APC/C substrates Cyclin B and geminin in HeLa cell lysates, and this 
inhibition was not observed when lysates were treated with the TRIM39 RING domain 
mutant (C44A). The inhibition is directly mediated by the action of TRIM39 on APC/C 
because TRIM39 can inhibit APC/C targeted Cyclin B ubiquitylation in vitro.  
Understanding the regulation of the APC/C is valuable for expanding our 
knowledge of cell cycle progression and other functions such as neuron growth where 
the APC/C is involved. TRIM39 provided a novel angle from which to investigate the 
mechanism of APC/C inhibition. From our work, we have found that the inhibition is 
not due to competition between the APC/C and TRIM39 for a common E2 ligase, 
because supplementation with excess UbcH10 (an APC/C E2) did not prevent TRIM39-
mediated APC inhibition. Given that the RING domain is required for this inhibition 
and we know that TRIM39 can interact with subunits of the APC/C (data not shown), 
the observed inhibition could be the result of ubiquitylation of APC/C subunits by 
TRIM39, thereby preventing APC/C assembly or substrate recruitment.  Interestingly,  
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preventing APC/C assembly has been reported as a mechanism of inhibition  by the 
chicken anemia virus protein, Apoptin which inhibits APC/C formation by association 
with APC1 and release of Cdc27 and APC1 from the APC/C (Teodoro et al., 2004).  
It is also possible that the E3 ligase activity of TRIM39 is required primarily for 
auto-ubiquitylation.   In such a scenario, auto-ubiquitylated TRIM39 effectively 
competes with other APC/C substrates.  In this regard, it is interesting that TRIM39 
possesses two putative D-box motifs. We have found that TRIM39 auto-ubiquitylation 
may facilitate its inhibitory activity, since pre-ubiquitylating the TRIM39 C44A mutant 
with TRIM39 wild type protein can cause C44A protein inhibitory activity (data not 
shown). We are continuing to refine these findings by adjusting the pre-ubiquitylation 
time and protein levels. We have already received mass spectrometry data identifying 
the sites on TRIM39 modified by ubiquitylation. We will further determine whether 
TRIM39 mutant protein that is refractory to ubiquitylation loses its APC/C inhibitory 
ability.   
Alternatively, TRIM39 may act like Emi1, which has been shown to interfere with 
poly-ubiquitin chain elongation (Wang and Kirschner, 2013).  Similarly, our data 
demonstrate that Cyclin B is oligo-ubiquitylated instead of poly-ubiquitylated by APC/C 
in the presence of TRIM39, suggesting TRIM39 may alter the ubiquitin transfer 
efficiency from E2 to substrates of APC/C.   
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Mitotic cell death (or mitotic catastrophe) has been shown to kill transformed 
cells effectively. For example, microtubule inhibitors such as taxanes and the vinca 
alkaloids are used in breast, ovarian and lung cancer treatments (Zeng et al., 2010). 
These drugs induce SAC and inhibit the APC/C; therefore cells are arrested in prolonged 
mitosis and die. However, some cells can escape from SAC-enforced inhibition of the 
APC/C (mitotic slippage) and this slippage may reduce the cell death that occurs during 
prolonged mitosis. Moreover, these microtubule perturbation drugs have deleterious 
side effects because normal microtubule functions are required for vesicular trafficking 
and axonal transport (Chan et al., 2012). Therefore, finding a potential method to 
directly inhibit the APC/C without perturbing microtubules (perhaps by inducing 
TRIM39) might provide a means of targeting cancer cells. We have found TRIM39 can 
inhibit the APC/C in vitro and prevent degradation of Cyclin B and geminin in vivo. 
However, in the absence of DNA damage in p53-deficient cells, TRIM39 does not appear 
to have an overt cell cycle effect.  (Note: the G1/S arrest in TRIM39 depleted cells results 
from the accumulation of p53).   Thus, to activate TRIM39 ectopically will require either 
a simultaneous DNA damaging signal or in depth knowledge of the mechanism of 
activation.  
Interestingly, a chemical inhibitor of the APC/C, tosyl-L-arginine methyl ester 
(TAME), was shown to affect the activity of APC/CCdh1 only when Emi1 is ablated in cells 
(Zeng et al., 2010).  Likewise, TRIM39 depletion may not have any effect due to masking 
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by other dominant inhibitors of the APC/C.  Therefore, I propose to examine the cell 
cycle effects of TRIM39 by overexpressing TRIM39 proteins in Emi1 or Mad2/BubR1 
depleted cells. Additionally, if we identify which regions of ubiquitylated TRIM39 
potentiate its ability to inhibit the APC/C and which regions are required for 
binding/inhibiting the APC/C, we may be able to  design a peptide contains the relevant 
ubiquitin modifications and can serve as a potent APC/C inhibitor. .  
4.2 APC/C contributes to apoptotic signaling    
In chapter 2, the data demonstrate that Cdh1 interacts with the Bax activator 
MOAP-1 through D-boxes on MOAP-1. This interaction triggers APC/C ubiquitylation 
of MOAP-1 and promotes MOAP-1 destruction. We also found that Cdh1 depletion 
enhanced MOAP-1 protein expression in cells, and consequently, Cdh1 depleted cells 
have a greater apoptotic response when treated with etoposide and cisplatin.   
As discussed previously, APC/CCdc20 can target the anti-apoptotic protein Mcl-1 
after prolonged mitotic arrest to induce apoptosis (Harley et al., 2010).  This apoptotic 
signal could be strengthened via MOAP-1 before MOAP-1 is degraded by APC/CCdh1. In 
addition, the APC/CCdh1 substrate Cyclin B together with Cdk1 can mediate inhibitory 
phosphorylation on caspase-2, caspase- 8 and caspase-9 during mitosis, suggesting that  
the APC/CCdh1 utilizes its substrates to fine tune the threshold of apoptosis during 
mitotic exit (Allan and Clarke, 2007) (Andersen et al., 2009) (Matthess et al., 2010).    
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Etoposide and cisplatin cause G2/M arrest and apoptosis in p53 mutant cells. We 
found that Cdh1 depletion enhances DNA damage drug induced apoptosis in 293T, 
PC3, and H1299 cells, as well as in a panel of p53 mutant cells (data not shown), and that 
cell death can be attenuated after MOAP-1 depletion. Interestingly, the viral proteins 
Apoptin and E4orf4 both cause apoptosis following G2/M arrest in p53 mutant cells 
(Kornitzer et al., 2001) (Teodoro et al., 2004) and APC/C inhibition leads to an increased 
cell death response in these p53 mutant cells overexpressing viral proteins . These 
studies suggest that inhibition of the APC/C sensitizes cells to virus induced apoptosis 
and raise the possibility of MOAP-1 involvement in this process.          
4.3 TRIM39 is a negative regulator of p53 
In chapter 3, we found that TRIM39 depletion causes G1/S arrest and reduced 
proliferation in RPE cells. We also determined that this arrest resulted from p21 
induction after p53 stabilization. This increased amount of p53 is because of loss of the 
p53 E3 ligase TRIM39. We showed that TRIM39 can interact with p53 and promote its 
proteosomal degradation after polyubiquitylation. This function is, again, RING domain 
dependent. In contrast, this function is independent of APC/C inhibition by TRIM39 and 
is independent of the predominant p53 E3 ligase MDM2. We also demonstrated that the 
importance of TRIM39 is cell type dependent; for example, cell cycle arrest is more 
obvious in TRIM39 depleted RPE and A549 cells, as compared to MCF7 and 22Rv1 cells. 
 117 
These findings suggest that various E3 ligases of p53 are differentially necessary for p53 
regulation in specific tissues, specific conditions, and specific stresses. 
       These findings also help to explain the puzzle of why apoptosis is not always 
reduced after TRIM39 depletion in some cells where MOAP-1 protein level should 
already be decreased (chapter 2, data not shown). Interestingly, p53 is also required for 
the DNA damage induced-activation of APC/C in G2 (Wiebusch and Hagemeier, 2010). 
The finding that the APC/C activates after DNA damage was initially confusing, because 
our data indicate that the APC/C should be weakened to maintain MOAP-1 expression 
in response to DNA damage.  In p53 wildtype U2OS or HCT116 cells, DNA damage 
caused premature activation of the APC/C and led to the destruction of the APC/C 
substrate Plk1, an important mitotic kinase (Bassermann et al., 2008). These data suggest 
that DNA damage induced G2 arrest in p53 wildtype cells may due to decreased Plk1 
resulting from premature activation of the APC/C. This is quite interesting, since we 
observe that Plk1 inhibition by treating with either a Plk1 inhibitor or a siRNA targeting 
Plk1 can both reduce TRIM39 protein expression (Fig. 4.1A, 4.1B). Since decreased 
TRIM39 increases p53 protein, it will be interesting to see whether DNA damage 
initiated G2 arrest in p53 wildtype cells is augmented by TRIM39. On the other hand, 
cells without normal p53 will eventually bypass G2 arrest and enter into mitosis where 
TRIM39 levels can be maintained (since Plk1 is high in prometaphase) and can restrain 
APC/C activity for MOAP-1 destruction and trigger apoptosis once the damage is too 
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severe to be recoverable (Bunz et al., 1998; Giono and Manfredi, 2006). We are still trying 
to understand how TRIM39 is regulated by Plk1 and how TRIM39 affects p53 induction 
in G2 arrest phase after DNA damage. Moreover, we are working on elucidating 
whether apoptosis induced by Plk1 inhibition is TRIM39 dependent. This is important to 
investigate, because Plk1 inhibitors have been used for clinical trials, and understanding 
the involvement of TRIM39 could help to identify biomarkers that would aid in deciding 
whether a patient could benefit from Plk1 inhibitor treatment (Plyte and Musacchio, 
2007) (Yim, 2013.) The proposed model is in Figure. 4.2.  
Given down-regulation of p53 is common during cancer development, we 
postulated that high expression of TRIM39 might lead to p53 inactivation and enhanced 
tumor occurrence. We analyzed TRIM39 gene expression in cancer samples using 
cBioPortal database and we found the frequency of TRIM39 gene amplification is 
slightly higher in ovary, melanoma and liver cancers (Fig. 4.3) (Cerami et al., 2012) (Gao 
et al., 2013). At this stage, we do not know whether the protein is also overexpressed and 
might contribute to cancer development.   However, the information from cBioPortal  is 
suggestive; we will be interested in determining whether TRIM39 protein levels are 
higher in these types of cancer as well as whether p53 and TRIM39 protein levels are 
inversely correlated  in these types of cancer. This research will help us gain more 
knowledge of the role of TRIM39 and may provide insights of value for cancer therapy.  
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4.4 The regulation of TRIM39 
The E3 ligase TRIM39 can inhibit the APC/C, and this inhibition is essential for 
apoptosis induction upon DNA damage. The apoptosis proceeds via the release of 
cytochrome c from the mitochondria, which is controlled by Bcl-2 family proteins, 
particularly the pro-apoptotic protein Bax. The APC/C constitutively ubiquitylates the 
Bax-activator protein MOAP-1 and TRIM39 prevents this modification when cells are 
treated with DNA damaging reagents.  We speculate that DNA damage response 
signaling is involved in the regulation of MOAP-1 stability, and this stability change is 
likely through altered TRIM39 activity. Indeed, we found that MOAP-1 protein is not 
elevated when cells are treated with Chk1 or ATR/M inhibitors one hour prior to  
etoposide treatment. In contrast, MOAP-1 protein expression is induced in cells treated 
with only etoposide, Chk2 inhibitor plus etoposide and Cdk1 inhibitor plus etoposide 
(Fig. 4.4A, 4.4B). Moreover, we found that TRIM39 ligase activity is increased by DNA 
damage, since we observed more ubiquitin conjugation on purified overexpressed or 
endogenous TRIM39 from etoposide treated lysates after incubating TRIM39 with E1, 
E2, ATP and ubiquitin (Fig. 4.5A, 4.5B).  This increase in ligase activity is likely to 
explain the enhanced inhibitory activity toward the APC/C, since we have found that 
the inhibition requires TRIM39 ligase activity. We hypothesized that increased MOAP-1 
levels resulted from increased TRIM39 ligase activity. Because the MOAP-1 level is 
changed when Chk1 is inhibited, we believe that the change stems from altered ligase 
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activity of TRIM39. As shown in Fig. 4.4C, ubiquitylation on TRIM39 is decreased in 
Chk1 depleted cells. These data are still preliminary as we don’t know yet whether the 
ubiquitylation of TRIM39 in this setting is due to autoubiquitylation of ubiquitylation by 
another E3 ligase. We also need to further confirm whether Chk1 directly interacts with 
or phosphorylates TRIM39 to modulate its activity. It will be of interest to see how Chk1 
signaling affects TRIM39 autoubiqutylation. MDM2 auoubiquitylation is reported to 
facilitate the interaction of E2-Ub and its substrates (Ranaweera and Yang, 2013). 
Therefore, DNA damage induced autoubiquitylation of TRIM39 may enhance its ability 
to inhibit the APC/C to stabilize MOAP-1.  
TRIM39 isoforms can also auto-regulate TRIM39. As reported by another group 
also studying TRIM39, the half life of isoform 1 is short and the half life of isoform 1 is 
extended by associating with isoform 2 (used in our experiments). They also suggested 
that both isoforms of TRIM39 are required for preventing p21 ubiquitylation by CRL4Cdt2 
in HCT116 cells (Zhang et al., 2012b). By forming a complex with p21, the two isoforms 
protect p21 from interacting with Cdt2. Intriguingly the p21 stabilization effect is neither 
E3 ligase dependent nor p53 dependent. In our hands, we observed p21 protein level is 
increased in TRIM39 depleted cells. We initially thought the discrepancy was due to a 
cell context dependent function of TRIM39 and we did not examine p21 levels in 
HCT116 cells at that time. However, we found that p21 is induced rather than decreased 
after TRIM39 depletion in RPE, MCF7, A549, 22Rv1 and HepG2 cells. Moreover, the 
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report is controversial since we observed less EdU incorporation after TRIM39 knock-
down in HCT116, A4549, U-87MG, 22Rv1 and HepG2 cells whereas the group found 
opposite effect only in HCT116 cells. Therefore, whether p21 is really stabilized by 
interacting with TRIM39 still needs to be confirmed.  
4.5 TRIM family modulates p53  
We found that TRIM39 is a p53 ubiquitin E3 ligase. Interestingly, TRIM24 is also 
reported to target p53 for ubiquitylation and degradation (Allton et al., 2009). Besides 
the direct interaction with p53, there are other TRIM39 family proteins reported to 
modulate p53 stability. For example, PML (TRIM19) can sequester MDM2 to nucleolar 
caps to prevent p53 degradation once TRIM19 is phosphorylated by ATR after DNA 
damage (Bernardi et al., 2004). TRIM8 and TRIM13 both are reported to stabilize p53 by 
mediating MDM2 degradation (Caratozzolo et al., 2012) (Joo et al., 2011). Moreover, 
TRIM28 is reported to promote MDM2 mediated ubiquitylation on p53 by forming a 
complex with MAGE protein, which enhances MDM E3 ligase activity, interacting with 
MDM2 and decreasing acetylation of p53 (Doyle et al., 2010) (Wang et al., 2005). Besides 
affecting stability, TRIM29 is reported to repress the transcriptional activity of p53 by 
interacting with p53, promoting its nuclear export and by inhibiting its Lys120 site 
acetylation (Yuan et al., 2010b) (Yuan et al., 2010a). 
  TRIM proteins can form homodimers or heterodimers, which confer upon them 
a variety of substrate specificities or actions under different physiological conditions.  
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Therefore, these TRIM proteins could form heterodimers to regulate p53. Interestingly, 
TRIM39 can form a heterodimer with TRIM13 and TRIM13 protein is reported to 
promote MDM2 degradation. Therefore, I speculate that the degradation of p53 by 
TRIM39 will be counteracted by TRIM13 in cells that have both MDM2 and TRIM13 E3 
ligase. It could also be possible that TRIM13 is sequestered by TRIM39, thereby 
preventing MDM2 degradation and promoting p53 destruction. In order to understand 
more physiological functions of TRIM39, it will be interesting to see how homodimers of 
TRIM39 and how heterodimers of TRIM39/13  influence TRIM39 E3 ligase activity and 
alter p53 stability (Horie-Inoue, 2013) Additionally, TRIM39 homodimerization may be 
important for its nuclear localization since its homologue Xnf7 has been reported to form 
homotrimers for enabling its chromosome association (Beenders et al., 2007).   Thus, 
fully understanding the function and activity of TRIM39 may require the study of its 
oligomerization.    
4.6 Concluding marks 
The data presented in this dissertation have advanced our knowledge of how cell 
cycle and apoptosis are regulated by TRIM39 through the APC/C and p53. We found 
that TRIM39 is a RING domain E3 ligase that can autoubiquitylate and ubiquitylate 
substrates. We also demonstrate that TRIM39 is an inhibitor of the APC/C, and this 
inhibition prevents MOAP-1 destruction, which ultimately sensitizes p53 negative cells 
to chemotherapy drug induced apoptosis. In addition, we discovered that TRIM39 is a 
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ubiquitin E3 ligase for p53, which promotes the transcription of p21 and Bax. Therefore, 
TRIM39 expression and activity can modulate G1/S arrest and apoptosis.  
Given the roles of the APC/C as a cell cycle gatekeeper essential for restricting 
cell division and p53 as a genome guardian critical for ensuring checkpoint or apoptosis 
response when facing stresses, understanding TRIM39 which controls both the APC/C 
and p53 may help  to develop potential novel therapeutics for treating cancers and other 
diseases.  
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Figure 4. 1: Inhibition of Plk1 decreases TRIM39 amount. 
Figure 4.1: (A) 293T cells were treated with 1 µM Chk1 inhibitor Go6976, 0.4 µM Chk1 
inhibitor Pf47736 and 0.02 µM Plk1 inhibitor BI6727 for 8 h then cells were collected and 
lysed. Cell lysates were analyzed by western blot and immunoblotted with indicated 
antibodies. (B) 293T cells were transfected with control (Ctl), Plk1 targeted siRNA (Plk1a 
and Plk1b) for 2 d. Cells were collected and lysed for analysis. 
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Figure 4. 2: Proposed model of TRIM39 signaling in p53 wildtype or mutant 
cells. 
Figure 4.2: In p53 wildtype (WT) cells, DNA damage occurred after S phase will activate 
ATM/R which is followed by Chk1 activation and Plk1 inhibition. Chk1 activation leads 
to p53 accumulation which is required for sustained G2 arrest and the APC/C activation 
in G2. We also propose the inhibition of Plk1 will also decrease the amount of TRIM39, 
thereby preventing TRIM39 inhibition on the APC/C. p53 accumulation and the APC/C 
activation decreases the amount and activity of Cyclin B/Cdk complexes and arrests cells 
at G2 phase. Meanwhile, p53 will enhance apoptosis by upregulating pro-apoptotic 
genes. In some situations, p53 mutant cells will bypass G2 arrest and cells enter mitosis. 
At this stage, Plk1 may increase TRIM39 abundance and Chk1 may enhance TRIM39 
ligase activity to inhibit the APC/C. Therefore, MOAP-1 is accumulated and stimulates 
apoptosis. (Green line: activation. Red line: inhibition. Dotted line: weak activity. )    
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Figure 4. 3: Genomic alternation of TRIM39 analysis across various cancer 
types. 
Figure 4.3: The figure is analyzed from cBioPortal database. X-axis represents various 
cancer types and Y-axis indicates the TRIM39 gene alternation frequency which is found 
in the samples collected by cBioPortal database. Amplification of TRIM39 (red rectangle) 
may correlate with the development of ovary, melanoma and liver cancers.  
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Figure 4. 4: Chk1 affects etoposide induced MOAP-1 stability and TRIM39 
ubiquitylation. 
Figure 4.4: (A) 293T Cells were treated with Chk1 inhibitor 1 µM Go6976 and 0.4 µM 
PF47736 one hour earlier than 100 µM etoposide tretment. After 24 h, cells were 
collected and lysed for analysis. (B) 293T Cells were treated with chemical inhibitors as 
indicated concentration and 1 hour in advance than 100 µM etoposide for 24 h. Cells 
were collected and lysed for immunoblotting. (C) 293T cells were transfected with 
control or Chk1 targeted siRNA. After 1 day, cells were transfected with Myc-TRIM39 
plasmids and next day cells were treated with 100 µM etoposide another day. Cell were 
lysed and immunoprecipitated with anti-Myc antibody.  
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Figure 4. 5: DNA damage increases TRIM39 ligase activity 
Figure 4.5: (A) 293T cells were transfected with 4 ug Myc-TRIM39 WT or C44A plasmid 
for 24 h and treated with 100 µM etoposide for another 24 h before collecting. Cells were 
lysed and IP with Myc antibody for 6 h. Immunoprecipitated complexes were incubated 
with E1, E2, ATP, and Ub at 30 °C for 45 min. (B) 293T cells were treated with 100 µM 
etoposide for 24 h. Cells lysates were made and IP was performed using TRIM39 
antibody. Immunoprecipitated complex containing TRIM39 was used for in vitro 
ubiquitylation assay and samples were resolved in SDS-PAGE and examined by western 
blotting.  
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